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Age-related macular degeneration (AMD) is a leading cause of irreversible 
blindness among adults, age 60 and older, in developed countries. While oxidative stress 
is implicated in the pathogenesis of AMD, clinical studies have shown that dietary 
antioxidants can delay progression of AMD. Currently, there is no FDA-approved 
treatment for AMD. Therefore, we hypothesized that N-acetylcysteine amide (NACA), a 
thiol antioxidant, would protect retinal pigment epithelium and impede the progression of 
retinal degeneration. The goal of this work was to evaluate the efficacy of NACA in 
preventing retinal pigment epithelial cell and photoreceptor death in AMD models. To 
achieve this, we used the oxidants tert-butyl hydroperoxide (TBHP) and sodium iodate 
(NaIO3) in a cell model and an animal model to evaluate the effects of NACA. Our data 
suggest that pretreatment with NACA reduces the sub-lethal (but not lethal) effects of 
TBHP in primary cultures of human retinal pigment epithelial cells. NACA significantly 
improves cell survival when administered prior to and during the occurrence of oxidative 
damage similar to that observed in the development of dry AMD. In the chemically- 
induced retinal degeneration animal model, NACA eye drops partially prevented 
reduction in visual function, as determined from electroretinograms (ERG) recorded 36 
hours after NaIO3 injection. Other toxic effects were observed at a later time point after 
NaIO3 injection: increased lipid peroxidation (as measured by formation of 4-
hydroxynonenal, 4-HNE), elevated cysteine levels, and death of photoreceptors resulting 
in outer nuclear layer thinning. NACA eye drops reversed these toxic effects. In 





The work presented in this doctoral dissertation reflects the supportive 
environment I have enjoyed at Missouri University of Science and Technology. I would 
like to express my deepest gratitude to my advisor, Dr. Nuran Ercal, for the opportunity 
to work on this meaningful project. Her guidance helped me throughout my research and 
writing this dissertation. Also, I would like to thank my co-advisor, Dr. Robert Aronstam, 
for his advice and endless support from the first day we met. Besides my advisor and co-
advisor, I am very appreciative of my committee members: Dr. Shubhender Kapila, Dr. 
Jeffrey G. Winiarz, and Dr. Klaus Woelk, and sincerely thank them for their 
encouragement and advice. My sincere thanks also go to Dr. Yue-Wern Huang, Dr. 
Humeyra Karacal, Daniel Lindgren, and Dr. Teresa Doggett for their technical support 
and assistance with the manuscript. In addition, I very much appreciate the support of my 
lab mates in Dr. Ercal’s and Dr. Aronstam’s groups: Dr. Shakila Tobwala, Dr. Sri 
Krishna Yasaswi Maddirala, Dr. Ahdab Khayyat, Justin Beltz, Barbara Harris, and Dr. 
Adam Martin. Their stimulating discussions, helpful suggestions, and labor-intensive 
dosing and sample collection for animal projects, contributed significantly to completion 
of this project. Special thanks go to my exceptional team member, Annalise Pfaff, who 
labored greatly to help with my research. My gratitude is also expressed to Dr. Louis 
Chang, who encouraged me to leave Taiwan, and assisted me in striving for my PhD at 
Missouri S&T. I am also extremely thankful for the endless support and love of my 
parents, family members, and husband, Michael R. Little. Finally, the financial support 
for this work has been provided by the U.S. National Eye Institute, NIH (Grant No: 
R15EY022218-01), and the Richard K. Vitek Endowment.  
vi 
 
TABLE OF CONTENTS 
Page 
PUBLICATION DISSERTATION OPTION ................................................................... iii 
ABSTRACT ....................................................................................................................... iv 
ACKNOWLEDGEMENTS ................................................................................................ v 
LIST OF ILLUSTRATIONS ............................................................................................ xii 
LIST OF TABLES ........................................................................................................... xvi 
LIST OF ABBREVIATIONS ......................................................................................... xvii 
SECTION ............................................................................................................................ 1 
1. INTRODUCTION ...................................................................................................... 1 
1.1. OXIDATIVE STRESS ....................................................................................... 1 
1.1.1. The Definition of ROS. ................................................................................... 2 
1.1.2. Sources of ROS. .............................................................................................. 2 
1.1.3. Redox Balance and Oxidative Stress. ............................................................. 3 
1.1.4. Oxidative Damage By-Products and Their Formation. .................................. 6 
1.2. ANTIOXIDANTS............................................................................................. 10 
1.2.1. Glutathione. ................................................................................................... 13 
1.2.2. Glutathione Reductase. ................................................................................. 15 
1.2.3. Glutathione Prodrugs and N-Acetylcysteine Amide (NACA)...................... 16 
1.3. EYE ANATOMY AND PHYSIOLOGY ......................................................... 18 
1.3.1. Eye Anatomy. ............................................................................................... 18 
1.3.2. Retina. ........................................................................................................... 19 
1.4. AGE-RELATED MACULAR DEGENERATION .......................................... 19 
1.4.1. What is AMD? .............................................................................................. 19 
vii 
 
1.4.2. Risk Factors for AMD. ................................................................................. 21 
1.4.3. How Does Oxidative Stress Contribute to AMD? ........................................ 23 
1.4.4. Treatment and the Results of Age-Related Eye Disease Study (AREDS). .. 24 
1.4.5. The Protective Effect of NACA in Eye-Related Research. .......................... 26 
1.5. OTHER OXIDATIVE-STRESS RELATED EYE DISORDERS ................... 26 
1.5.1. Cataract. ........................................................................................................ 28 
1.5.2. Glaucoma. ..................................................................................................... 29 
1.5.3. Diabetic Retinopathy (DM). ......................................................................... 30 
1.5.4. Retinitis Pigmentosa (RP). ............................................................................ 31 
1.5.5. Autoimmune Uveitis. .................................................................................... 31 
1.5.6. Pseudoexfoliation Syndrome (PEX). ............................................................ 31 
2. EXPERIMENTAL DESIGN .................................................................................... 33 
3. MATERIALS & METHODS ................................................................................... 36 
3.1. MATERIALS .................................................................................................... 36 
3.2. CELL CULTURE CONDITIONS .................................................................... 36 
3.3. CELL VIABILITY ASSAY ............................................................................. 37 
3.4. INTRACELLULAR REACTIVE OXYGEN SPECIES (ROS) 
MEASUREMENT ............................................................................................ 38 
3.5. QUANTIFICATION OF INTRACELLULAR GLUTATHIONE (GSH)     
AND CYSTEINE LEVELS. ............................................................................ 39 
3.6. GLUTATHIONE REDUCTASE (GR) ACTIVITY ASSAY. ......................... 42 
3.7. QUANTIFICATION OF TOTAL PROTEIN .................................................. 43 
3.8. DEXTRAN PERMEABILITY AND TRANSEPITHELIAL ELECTRICAL 
RESISTANCE (TEER) MEASUREMENT ..................................................... 44 
3.9. FLOW CYTOMETRY QUANTIFICATION OF APOPTOTIC CELLS ........ 45 
3.10. ANIMAL MODEL AND EXPERIMENTAL DESIGN .................................. 46 
viii 
 
3.11. ELECTRORETINOGRAPHY (ERG) .............................................................. 46 
3.12. HEMATOXYLIN AND EOSIN (H&E) STAINING ....................................... 50 
3.13. OUTER NUCLEAR LAYER (ONL) THICKNESS MEASUREMENT ......... 50 
3.14. 4-HYDROXYNONENAL (4-HNE) IMMUNOHISTOCHEMISTRY 
STAINING AND QUANTIFICATION .......................................................... 50 
3.15. SDS-PAGE AND WESTERN BLOT FOR PTEN AND PHOSPHO-PTEN   
(P-PTEN) ANALYSIS. .................................................................................... 51 
3.16. STATISTICAL ANALYSIS ............................................................................ 51 
BIBLIOGRAPHY ............................................................................................................. 52 
PAPER .............................................................................................................................. 62 
I.  THE ROLE OF N-ACETYLCYSTEINE AMIDE IN DEFENDING PRIMARY 
HUMAN RETINAL PIGMENT EPITHELIAL CELLS AGAINST TERT-BUTYL 
HYDROPEROXIDE-INDUCED OXIDATIVE STRESS .......................................... 62 
ABSTRACT ...................................................................................................................... 63 
1. INTRODUCTION .................................................................................................... 64 
2. MATERIALS AND METHODS .............................................................................. 66 
2.1. MATERIALS ..................................................................................................... 66 
2.2. HRPEPIC CULTURE AND EXPERIMENTAL DESIGN ............................... 66 
2.3. CELL VIABILITY ASSAY .............................................................................. 67 
2.4. INTRACELLULAR ROS MEASUREMENT .................................................. 67 
2.5. QUANTIFICATION OF INTRACELLULAR GLUTATHIONE (GSH) 
LEVELS ............................................................................................................. 67 
2.6. GLUTATHIONE REDUCTASE (GR) ACTIVITY ASSAY ........................... 67 
2.7. DETERMINATION OF PROTEIN .................................................................. 67 
2.8. DEXTRAN PERMEABILITY AND TRANSEPITHELIAL ELECTRICAL 
RESISTANCE (TEER) MEASUREMENT ...................................................... 68 
2.9. FLOW CYTOMETRY QUANTIFICATION OF APOPTOTIC CELLS ......... 68 
2.10. STATISTICAL ANALYSIS ........................................................................... 68 
ix 
 
3. RESULTS ................................................................................................................. 69 
3.1. TBHP INCREASED INTRACELLULAR ROS LEVELS IN HRPEPIC,     
AND NACA PREVENTED ROS GENERATION ........................................... 69 
3.2. DOSE-DEPENDENT GSH DEPLETION BY TBHP AND PREVENTION   
BY PRETREATMENT WITH NACA .............................................................. 70 
3.3. PRESERVATION OF GLUTATHIONE REDUCTASE ACTIVITY BY 
PRETREATMENT WITH NACA .................................................................... 71 
3.4. EFFECTS OF OXIDATIVE STRESS ON HRPEPIC MONOLAYER 
PARACELLULAR PERMEABILITY AND CONTRIBUTION OF NACA   
TO MONOLAYER FUNCTIONAL HOMEOSTASIS .................................... 71 
3.5. CELL VIABILITY AND LETHAL EFFECTS OF TBHP ON HRPEPIC ....... 72 
3.6. ANNEXIN V-FITC AND 7-AMINOACTINOMYCIN-D (7-AAD) 
DETECTION OF APOPTOSIS BY FLOW CYTOMETRY ............................ 73 
4. DISCUSSION ........................................................................................................... 76 
5. CONCLUSION ......................................................................................................... 79 
ACKNOWLEDEMENTS ............................................................................................. 79 
CONFLICT OF INTEREST ......................................................................................... 79 
ABBREVIATIONS ...................................................................................................... 80 
SUMMARY .................................................................................................................. 80 
REFERENCES ............................................................................................................. 81 
II.  N-ACETYLCYSTEINE AMIDE (NACA) EYE DROPS PARTIALLY PREVENT 
THE LOSS OF VISUAL FUNCTION AND RETINAL DAMAGE IN A 
CHEMICALLY-INDUCED RETINAL DEGENERATION ANIMAL MODEL ...... 85 
ABSTRACT ...................................................................................................................... 86 
1. INTRODUCTION .................................................................................................... 87 
2. MATERIALS AND METHODS .............................................................................. 90 
2.1. MATERIALS ..................................................................................................... 90 
2.2. ANIMAL MODEL AND EXPERIMENTAL DESIGN ................................... 90 
2.3. ELECTRORETINOGRAPHY (ERG) ............................................................... 91 
x 
 
2.4. HEMATOXYLIN AND EOSIN (H&E) STAINING........................................ 92 
2.5. OUTER NUCLEAR LAYER (ONL) THICKNESS MEASUREMENT .......... 92 
2.6. 4-HYDROXYNONENAL (4-HNE) IMMUNOHISTOCHEMISTRY 
STAINING AND QUANTIFICATION ............................................................ 92 
2.7. MEASUREMENT OF INTRACELLULAR GLUTATHIONE (GSH) AND 
CYSTEINE LEVELS ........................................................................................ 93 
2.8. SDS-PAGE AND WESTERN BLOT FOR PTEN AND PHOSPHO-PTEN    
(P-PTEN) ANALYSIS....................................................................................... 93 
2.9. STATISTICAL ANALYSIS ............................................................................. 94 
3. RESULTS ................................................................................................................. 94 
3.1. PARTIAL PREVENTION OF SODIUM IODATE-INDUCED VISUAL   
LOSS BY NACA ............................................................................................... 94 
3.2. NACA PREVENTS OXIDATIVE DAMAGE AND OUTER NUCLEAR 
LAYER (ONL) THINNING .............................................................................. 95 
3.3. EFFECTS OF NAIO3-INJECTION AND NACA EYE DROPS ON    
RETINAL GSH AND CYSTEINE LEVELS.................................................... 95 
3.4. REDUCTION OF LIPID PEROXIDATION BY-PRODUCT 4-HNE BY 
NACA IN ONL .................................................................................................. 98 
3.5. PTEN AND PHOSPHORYLATED-PTEN (P-PTEN) IN THE RETINA ........ 99 
4. DISCUSSION ......................................................................................................... 100 
5. CONCLUSIONS..................................................................................................... 105 
ACKNOWLEDGEMENTS ........................................................................................ 106 
REFERENCES ........................................................................................................... 106 
SECTION ........................................................................................................................ 113 
4. PRELIMINARY DATA FOR IN VITRO MODEL ............................................... 113 
4.1. RESULTS ....................................................................................................... 113 
4.1.1. Protection by NACA Against Sodium Iodate-Induced Cell Death. ........... 113 
4.1.2. The Protective Effect of NACA Against NaIO3-Induced ROS Formation     
in HRPEpi Cells. ........................................................................................ 113 
xi 
 
4.1.3. Intracellular Glutathione Levels. ................................................................ 115 
4.1.4. Glutathione Reductase Activity. ................................................................. 116 
5. PRELIMINARY DATA FOR IN VIVO MODEL ................................................. 117 
6. CONCLUSION ....................................................................................................... 119 
APPENDIX ..................................................................................................................... 121 





LIST OF ILLUSTRATIONS 
 Page  
Figure 1.1 Reactive oxygen species and reactive nitrogen species .................................... 1 
Figure 1.2 The Lewis structures for molecular oxygen and its singlet electron    
derivatives superoxide, hydrogen peroxide, and hydroxyl radical ................... 2 
Figure 1.3 Formation of ROS through energy- and electron-transfer reactions. ................ 3 
Figure 1.4 The ROS generation in the mitochondria .......................................................... 4 
Figure 1.5 Sources and generation of different reactive oxygen species. ........................... 5 
Figure 1.6 Mechanisms of redox homeostasis: balance between ROS production and 
various types of scavengers .............................................................................. 5 
Figure 1.7 Oxidative stress-induced diseases in humans .................................................... 6 
Figure 1.8 The four steps of lipid peroxidation. ................................................................. 8 
Figure 1.9 Chemical structures of 4-hydroxynonenal (4-hydroxy-trans-2-nonenal,          
4-HNE) and malondialdehyde (MDA). ............................................................ 8 
Figure 1.10 Reactions of hydroxyl radical with DNA bases and their major products ...... 9 
Figure 1.11 The structures of carbonyl derivatives produced by direct oxidation of   
amino acid side chains. .................................................................................. 10 
Figure 1.12 The structure of glutathione. .......................................................................... 13 
Figure 1.13 Glutathione synthesis and enzymes involved in GSH metabolite. ................ 14 
Figure 1.14 Relationship between GSH homeostasis and pathologies ............................. 15 
Figure 1.15 Sources of ROS, antioxidant defenses, and subsequent biological effects 
depending on the level of ROS production ................................................... 16 
Figure 1.16 The structures of (A) N-acetylcysteine and (B) N-acetylcysteine amide. ..... 17 
Figure 1.17 Horizontal section of the right eye. ............................................................... 18 
Figure 1.18  A cross-sectional diagram depicting the major structures of the eye is   
shown on the left, and an enlarged diagram of the neural retina,     
underlying the RPE, choroid, and sclera is shown on the right ................... 20 
xiii 
 
Figure 1.19 A normal macula (a) Color fundus photograph of a normal left macula.       
(b) Multilayer structure of a macula .............................................................. 22 
Figure 1.20 Fundus photographs and a cross section of H&E stain showing the 
histopathological features in different stages of age-related macular 
degeneration (AMD) ..................................................................................... 22 
Figure 1.21 Key role of oxidative stress in AMD pathogenesis. ...................................... 24 
Figure 1.22 The possible molecular events affecting chaperone function of                      
α‐crystallins during aging and diabetes and potential target points for 
modulation α‐crystallin chaperone function. ................................................. 28 
Figure 1.23 Key role of oxidative stress in glaucoma pathogenesis. ................................ 29 
Figure 1.24 Relationship between hyperglycemia, oxidative stress, and pathways 
associated with the pathogenesis of diabetic retinopathy .............................. 30 
Figure 1.25 Effects of antioxidants in preventing uveitis ................................................. 32 
Figure 2.1 The experimental hypothesis of NACA’s role in defending RPE cells     
against oxidative stress in a cell model. .......................................................... 33 
Figure 2.2 The experimental hypothesis of NACA’s role in defending against sodium 
iodate-induced retinal degeneration in an animal model. ............................... 34 
Figure 2.3 Experimental design for sodium iodate-induced retinal degeneration in 
C57BL/6 mice. ................................................................................................ 35 
Figure 3.1 Calcein-AM staining mechanism .................................................................... 37 
Figure 3.2 The measurement of ROS by CM-H2DCFDA. ............................................... 39 
Figure 3.3 Formation of fluorescent NPM-thiol adduct. .................................................. 40 
Figure 3.4 The above of HPLC chromatogram showing the separation of a derivatized 
mixed thiol standard. ....................................................................................... 41 
Figure 3.5 The above of HPLC chromatogram showing the separation of a derivatized 
retina sample. .................................................................................................. 41 
Figure 3.6 Reaction schematic for the BCA protein assay ............................................... 44 
Figure 3.7 The monolayer integrity measurement (A) TEER and (B) Dextran 





Figure 3.8 More pictures in conducting electroretinography. (A) The corneal electrode    
is placed between contact lenses and the cornea; (B) The placements of 
corneal electrode (red), skin electrode (green), and mask to introduce 
isoflurane; (C) and (D) The HMsERG system; (E) The isoflurane       
induction system. ............................................................................................ 47 
Figure 3.9 The program settings for the scotopic and photopic view in an ERG  
recording. ........................................................................................................ 48 
Figure 3.10 Diagram of the retina showing where the major components of the ERG 
originate ......................................................................................................... 49 
Figure 3.11 Electroretinogram (A) ERG waveform and (B) amplitude and implicit      
time measurement of the ERG waveform . ................................................... 49 
PAPER І 
Figure 1 Intracellular ROS levels were measured using DCF fluorescence…….……… 69 
Figure 2 Intracellular GSH levels in HRPEpiC…………………………....………….....70 
Figure 3 Preservation of glutathione reductase activity by NACA………….…….…….71 
Figure 4 Protective effects of NACA on paracellular permeability in HRPEpiC….……72 
Figure 5 Effects of NACA and TBHP on HRPEpiC cell viability……………...….……73 
Figure 6 Flow cytometry analysis of apoptotic cells following the modified                  
(co-exposure) protocol with NACA and TBHP……………………….……….75  
PAPER II 
Figure 1 Partial prevention of sodium iodate-induced retinal dysfunction…….………...96 
Figure 2 NACA prevents oxidative damage and outer nuclear layer thinning….……….97 
Figure 3 Thiol levels in retina………………………………………………….…….…..97 
Figure 4 Reduction of lipid peroxidation by-product formation in ONL….……….……98 
Figure 5 PTEN and phosphorylated-PTEN (p-PTEN) in the retina..…………………....99 
Figure 6 The calculated PTEN/p-PTEN ratio from Figure 5………………………...…100 
SECTION 
Figure 4.1 Comparison of NaIO3 cytotoxicity with and without NACA in HRPEpiC. . 114 
xv 
 
Figure 4.2 ROS levels in HRPEpiC after 4 hours of pretreatment with NACA and  
another 3 hours of treatment with increasing concentration of NaIO3. ........ 114 
Figure 4.3 Intracellular GSH levels in HRPEpiC. .......................................................... 115 
Figure 4.4 Glutathione reductase (GR) levels................................................................. 116 
Figure 5.1 Experimental design for rd10
+/+
 model......................................................... 117 
Figure 5.2 NACA eye drops prevented the reduction of ONL thickness in rd10
+/+





LIST OF TABLES 
 Page 
Table 1.1 The summary of protein modifications induced by reactive oxidants .............. 10 
Table 1.2 Enzymatic Antioxidant Defenses ...................................................................... 11 
Table 1.3 Non-Enzymatic Antioxidant Defenses ............................................................. 11 
Table 1.4 Summary of the risk factors of oxidative-stress related ocular diseases and     
the role of oxidative stress in pathogenesis of each ......................................... 27 
Table 3.1 Gradient program of mobile phase used in the HPLC separation .................... 40 
PAPER I 
Table 1. Percent distribution of viable cells and cells in the early and late stages of 
apoptosis after 4 hours of pretreatment with NACA followed by 3 hours of 
TBHP exposure……………………………………………………………..….74 
Table 2. Percent distribution of viable cells and cells in the early and late stages of 
apoptosis from Figure 6…….………………………………………………….75 
xvii 
 





AGEs advanced glycation end products 
AMD age-related macular degeneration 
annexin V-FITC annexin V -Fluorescein isothiocyanate 
AR aldose reductase 
AREDS Age-Related Eye Disease Studies 
CAT catalase  
CEP carboxyethylpyrrole 
CM-H2DCFDA 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate, acetyl ester 
DAG diacylglycerol 
DM diabetes mellitus 
DR diabetic retinopathy 
EDTA ethylenediaminetetraacetic acid 
eNOS endothelial nitric oxide synthase  
ERG electroretinogram 






G6PD glucose-6-phosphate dehydrogenase 
GADPH glyceraldehyde 3-phosphate dehydrogenase 
GCL γ-glutamylcysteine ligase 
GCL ganglion cell layer 
GCS glutamylcysteine synthetase 
GGT γ-glutamyltransferase 
GPx glutathione peroxidase 
GR GSH reductase 
GS glutathione synthetase 
GSH glutathione 
GSSG glutathione disulfide 
H&E Hematoxylin and Eosin 
H2O2 hydrogen peroxide  
HO
•
 hydroxyl radical  
HRPEpiC human retinal pigment epithelial cells 
INL inner nuclear layer 
IP intraperitoneal 








NADPH nicotinamide adenine dinucleotide phosphate 
NaIO3 sodium iodate 
NO˙ nitric oxide 
Nox NADPH oxidases  
NPDR non-proliferative diabetic retinopathy 




ONL outer nuclear layer 
OPL outer plexiform layer 
PARP poly-ADP-ribose polymerase 
PBS Phosphate buffered saline 
PDR proliferative diabetic retinopathy 
PDT photodynamic therapy 
PEX pseudoexofoliation syndrome 
PKC protein kinase C 
POS photoreceptor outer segments  
p-PTEN phospho-PTEN 
PRX peroxiredoxin 
PTEN phosphatase and tensin homolog deleted on 
chromosome ten 
PUFA polyunsaturated fatty acid 
ROO
•




ROS Reactive Oxygen Species 
RP retinitis pigmentosa 
RPE retinal pigment epithelium 
SDH sorbitol dehydrogenase 
SOD superoxide dismutase  
TBHP tert-butyl hydroperoxide 
TEER transepithelial electrical resistance  
TM trabecular meshwork 
TRX thioredoxin 
UDPGlcNAc uridine diphosphate-N-acetylglucosamine 






1.1. OXIDATIVE STRESS 
Oxidative stress results from an imbalance between reactive species and 
antioxidant defense processes, that lead to a highly oxidizing environment that is harmful 
to cells 
[1]
. The term “reactive species” includes both free radicals that contain one or 
more unpaired electrons, and non-radicals with strong oxidizing potential. It encompasses 
reactive oxygen, nitrogen, halogen, and sulfur species. Figure 1.1 shows the major 
reactive species relevant to physiological processes 
[2]
. This section will focus on the 
definition of reactive oxygen species (ROS), sources of ROS, redox balance, and 
oxidative stress and its by-products. 
 
 







1.1.1. The Definition of ROS. Reactive species, including ROS, play an 
important role in a cell’s life and death [3-5]. The National Cancer Institute defines ROS as 
“a type of unstable molecule that contains oxygen and easily reacts with other molecules 
in a cell.” These molecules can damage lipids, nucleic acids, and proteins, which can 
result in cell death. The terms “ROS,” “oxygen-derived species,” and “pro-oxidant 
species” are generally interchangeable in biological scientific literature [6]. ROS can be 
classified as radicals or non-radicals. Radicals are chemical species with an unpaired 
electron, such as superoxide (O2
•-
), hydroxyl radical (HO
•
) and peroxyl radicals (formed 
from non-radical lipid peroxides and peroxides of proteins and nucleic acids). Hydrogen 
peroxide (H2O2) is a non-radical, but it forms the most reactive free radical, hydroxyl 
radical (HO
•
), through the Fenton reaction. Figure 1.2 shows the Lewis structures of 
molecular oxygen, superoxide, hydrogen peroxide, and hydroxyl radical 
[7]
. Their energy- 






Figure 1.2 The Lewis structures for molecular oxygen and its singlet electron derivatives 





1.1.2. Sources of ROS. ROS can be generated endogenously or exogenously [6, 
9]
. Endogenous sources of ROS include leakage of electrons to O2 in the mitochondrial 
3 
 
respiratory chain (Figure 1.4) 
[10]
, direct or indirect generation by numerous enzymes, and 
the Fenton reaction (Figure 1.5) 
[11]
. In addition, certain diseased states may increase 
endogenous ROS production as a result of dysfunctional regulation of the immune 
response. High-energy electromagnetic radiation (UV, X-ray, and γ radiation), certain 
foods, medicines (acetaminophen, doxorubicin, and nitrofurantoin), and illicit drugs 
(methamphetamine and heroin), cigarette smoke, pollutants, and xenobiotics are common 






Figure 1.3 Formation of ROS through energy- and electron-transfer reactions (adapted 





1.1.3. Redox Balance and Oxidative Stress. ROS can play either beneficial or 
deleterious roles in the body. Certain ROS and their derivatives are involved in important 
physiological functions, such as regulation of vascular tone, control of erythropoietin 
production, and hypoxia-inducible functions, smooth muscle relaxation, signal 
4 
 
transduction, and maintenance of redox homeostasis 
[3]
. However, mitochondria-derived 
ROS can serve as a meditator of cell death in eukaryotes 
[17]
. ROS scavengers (also 
known as antioxidants) can remove extra ROS and stabilize the redox balance in cells. 
Figure 1.6 shows the mechanism of redox homeostasis 
[3]
. With an overwhelming 
production of ROS, the redox balance can be shifted toward a more oxidative status, in 
which the overproduction of ROS is associated with numerous disorders, such as 
Alzheimer’s disease, cardiovascular disease, atherosclerosis, cataract, and retinal 
degeneration 
[4, 9, 18]
. A summary of oxidative stress-induced diseases in humans is shown 
in Figure 1.7 
[4]
. More details about oxidative stress by-products and the role of oxidative 
damage will be discussed in the following sections. 
 
 







Figure 1.5 Sources and generation of different reactive oxygen species (adapted from 







Figure 1.6 Mechanisms of redox homeostasis: balance between ROS production and 














1.1.4. Oxidative Damage By-Products and Their Formation. An excess of 
ROS, especially hydroxyl (HO
•
) and peroxyl (ROO
•
) radicals, hydrogen peroxide (H2O2), 
and superoxide radical anion (O2
•ˉ
), is associated with oxidation-induced damage to 
DNA, proteins, and fatty acids. In this section, the formation of DNA oxidation by-
products, protein carbonyls, and lipid peroxidation by-products will be discussed. 
 Lipid peroxidation is a free radical chain reaction in which free radicals attack the 
carbon-carbon double bonds of polyunsaturated fatty acids (PUFAs), generating lipid 
hydroperoxides and electrophilic α,β-unsaturated carbonyl derivatives of these lipids [19]. 
Lipid peroxidation consists of three steps: initiation, propagation, and termination (see 
Figure 1.8) 
[12, 20]
. In the initiation step, a free radical (R
•
) attacks the methylene bridge (-
CH2-) of an unsaturated fatty acid and abstracts hydrogen to produce a lipid radical (a 
carbon radical). A stable conjugated diene is formed after molecules are rearranged 
7 
 
(Figure 1.8, step 1). In the propagation step, the lipid radical (carbon radical) reacts with 
O2 to form a new peroxyl radical (ROO
•
) (Figure 1.8, step 2), which abstracts H
•
 from an 
adjacent lipid, forming a lipid hydroperoxide (ROOH) plus a new lipid radical (Figure 
1.8, step 3) that will then continue the chain reaction. In the termination step, an 
antioxidant donates hydrogen to the lipid peroxyl radical (ROO
•
), resulting in a non-
radical product (Figure 1.8, step 4). Aldehydes, such as malondialdehyde (MDA) and 4-
hydroxynonenal (4-HNE), (Figure 1.9, 
[21]
) may also be formed during lipid peroxidation. 
MDA is mainly formed from the peroxidation of PUFAs with more than two double 
bonds, such as linolenic acid, arachidonic, and docosahexaenoic acid, whereas 4-HNE is 
formed during peroxidation of ω-6 (omega-6) PUFAs, such as linolenic acid and 
arachidonic acid 
[22]




DNA’s localization in the nucleus affords it some protection from ROS, and it is 
relatively stable under physiological conditions. DNA is not very susceptible to direct 
oxidative damage from weak ROS, such as O2˙
-
 , NO˙, and H2O2 
[24]
. However, when 
DNA (or RNA) is exposed to highly reactive OH˙, adducts may be generated. For 
example, OH˙ can attack guanine at C-8 to form 8-hydroxyguanine (8-OH-dG) [6]. Figure 
1.10 shows the modification of DNA bases by HO˙ radicals [25]. In addition, electrophilic 
lipid peroxidation by-products (such as MDA and 4-HNE) can cause DNA damage. 
MDA can react with DNA at a physiological pH to form the adducts deoxyguanosine, 
deoxyadenosine, and deoxycytidine 
[26]
. 4-HNE is the most genotoxic, while MDA is the 












Figure 1.9 Chemical structures of 4-hydroxynonenal (4-hydroxy-trans-2-nonenal, 4-





 There is a high abundance of protein in biological systems; therefore, proteins are 
often a target for oxidative damage. Proteins can be attacked by ROS directly or 
indirectly by lipid peroxidation by-products, and the resulting damaged proteins can 
affect enzyme activity or alter cellular functions 
[6]
. Protein carbonyls are the most well-
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known biomarkers for protein peroxidation and are associated with many human 
diseases, including diabetes, Alzheimer’s disease, and chronic lung disease [28]. Table 1.1 
lists the oxidants involved in protein oxidation and their major sites of reaction 
[29]
. Direct 
protein carbonylation often happens on the side chains of proline, arginine, lysine and 
threonine residues. Figure 1.11 shows the structures of carbonyl derivative products of 
amino acid side chains: 2-pyrrolidone from prolyl residues, glutamic semialdehyde from 
arginyl and prolyl residues, α-aminoadipic semialdehyde from lysyl residues, and 2-






Figure 1.10 Reactions of hydroxyl radical with DNA bases and their major products 






Table 1.1 The summary of protein modifications induced by reactive oxidants 
Oxidant Major sites of reaction 
HO
•






Cys, Met, Trp, Tyr 
NO2
•
 Cys, Tyr/Trp radicals 
O2
•ˉ
 Superoxide dismutase, some transition metal ions, Fe-S 
clusters, Tyr/Trp radicals 
1
O2 Cys, Met, Trp, Tyr, His 
HOCl/HOBr Cys, Met, cysteine, His, Lys, Trp, α-amino group 
Peroxynitrous acid (ONOOH) Cys, Met, Tyr, Trp 
Reactive aldehydes Cys, Arg, Lys, His, α-amino group 
UVB light Trp, Tyr, cystine 
H2O2 Cys, selenocysteine 
Cys, Cysteine; Met, Methionine; Trp, Tryptophan; Tyr, Tyrosine; His, Histidine; Lys, 






Figure 1.11 The structures of carbonyl derivatives produced by direct oxidation of amino 






The primary role of antioxidants is to neutralize excess ROS, thereby protecting 
the cell from their deleterious effects. Antioxidants can be classified as enzymatic or non-
enzymatic 
[4]
. Superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase, and 
thioredoxin are examples of enzymatic antioxidants (Table 1.2) 
[31, 32]
. The non-enzymatic 
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antioxidants can be further divided into metabolic antioxidants and nutrient antioxidants 
(Table 1.3) 
[31]
. Glutathione (GSH), melatonin, and α-lipoic acid are metabolic 
antioxidants. Vitamin E, vitamin C, carotenoids, omega-3 and omega-6 fatty acids, trace 
metals (selenium, manganese, and zinc), and flavonoids are nutrient antioxidants. 
Oxidative stress occurs when oxidants and antioxidants are not balanced in a cell, leaving 
excess oxidants to damage cellular components. 
 
 
Table 1.2 Enzymatic Antioxidant Defenses 
Enzymatic Antioxidants Catalyzed Reaction 

















 → Enzyme-Cu+ + H2O2 
Mn(Ш) + O2
•ˉ
 ⇆ [ Mn(Ш) - O2
•ˉ





 ⇆ [ Mn2+ - O2
•ˉ
 ]+ 2H
+→ Mn(Ш) + H2O2 
Catalase (CAT) 2H2O2 → O2 + 2H2O 
Catalase-Fe(Ш) + H2O2 → Compound І + H2O 
Compound І + H2O2 → Catalase-Fe(Ш) + H2O + O2 
Glutathione peroxidase  
(GPx) 
2GSH + H2O2  → GSSG + 2H2O 
2GSH + ROOH  → GSSG + H2O + ROH 
Thioredoxin (TRX) TRX-(SH)2 + Protein-S2 ⇆ TRX-S2 + Protein-(SH)2 
Peroxiredoxin (PRX) 2 R’-SH + ROOH ⇆ R’-S-S-R + H2O + ROH 
Glutathione transferase (GST) RX + GSH → R-S-GSH + HX 
RX: halogenated hydrocarbons 
[33]















 All trans retinol 
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1.2.1. Glutathione. Glutathione (γ-glutamylcysteinylglycine, GSH) is a water-
soluble endogenous tripeptide (structure in Figure 1.12) with γ-carboxyl groups that make 
this small peptide relatively more stable as compared to other peptides. GSH, the most 





Figure 1.12 The structure of glutathione. 
 
 
GSH cannot penetrate cell membranes; therefore, intracellular GSH must be 
synthesized through both de novo and salvage pathways (Figure 1.13, modified from 
[36, 
37]
). The first and rate-limiting step of de novo synthesis requires ATP and γ-
glutamylcysteine ligase (also known as γ-glutamylcysteine synthetase (GCS) [38]. Then, 
the dipeptide is combined with glycine by glutathione synthetase. The salvage synthesis 
pathways of GSH proceed via three different routes: reduction from GSSG, formation 
from the products of GSH hydrolysis, or production from amino acids and dipeptides 
transported into the cell by γ-glutamyl transpeptidase (Figure 1.13). GSH can be broken 







Figure 1.13 Glutathione synthesis and enzymes involved in GSH metabolite. 
GCL: γ-glutamylcysteine ligase, GS: Glutathione synthetase, GGT: γ-
glutamyltransferase (or γ-glutamyltranspeptidase), G6P: glucose-6-phosphate, G6PD: 
glucose-6-phosphate dehydrogenase, 6PG: 6-phosphogluconate, NADPH: nicotinamide 





The functions of GSH include antioxidant defense against reactive oxygen species 
(ROS) and electrophiles to maintain the cellular reducing environment, cysteine 
reservation, nitric oxide transportation, xenobiotic detoxification, and involvement in 
redox signaling-related transcription factor operations 
[36, 39]
. In the xenobiotic 
detoxification pathway, GSH can directly interact with excess ROS or conjugate with 
electrophile metabolites, which are then exported from the cell. Figure 1.14 shows the 
role of GSH in detoxification of xenobiotics and ROS balance, processes that may lead 
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to pathological conditions if dysregulated 
[36]
. The effects of an imbalance between 












1.2.2. Glutathione Reductase. GSH can be oxidized to glutathione disulfide 
(GSSG) by glutathione peroxidase (GPx).The function of the enzyme glutathione 
reductase (GR) is to reduce GSSG to GSH using NADPH generated by glucose-6-
phosphate dehydrogenase (G6PD) in the pentose phosphate pathway 
[38]
 (Figure 1.13). 
Patients with age-related macular degeneration (AMD) show both lower glutathione 









Figure 1.15 Sources of ROS, antioxidant defenses, and subsequent biological effects 





1.2.3. Glutathione Prodrugs and N-Acetylcysteine Amide (NACA). Direct 
administration of GSH as a therapeutic agent is ineffective because of its unfavorable 
biochemical and pharmacokinetic properties that limit its entry into cells. However, GSH 
prodrugs are able to replenish intracellular GSH levels and have been used as 
antioxidants for treatment of conditions associated with reduced GSH levels 
[42]
. There 
are two approaches for elevating intracellular GSH levels: GSH prodrugs or GSH co-
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drugs. GSH prodrugs are compounds with better bioavailability that can directly or 
indirectly increase intracellular GSH levels. GSH co-drugs consist of GSH covalently 
linked to another compound that both improves bioavailability and acts synergistically 
with GSH to produce the desired therapeutic effect. 
[42]
. GSH prodrugs can be divided 
into different categories: GSH esters, cysteinyl-modified GSH derivatives, and cysteine 
prodrugs 
[42]
. The most promising GSH prodrugs are the cysteine prodrugs, N-
acetylcysteine (NAC) and N-acetylcysteine amide (NACA) (their structures are shown in 
Figure 1.16). N-acetylcysteine (NAC), a thiol antioxidant, has been clinically used to 
treat various disorders and is already approved by the FDA (the U.S. Food and Drug 
Administration). However, NACA, the amide derivative of NAC, has been shown to be 
more effective because of its neutral charge, which increases its ability to permeate cell 
membranes and the blood-neural barrier 
[43]
. The protective effect of NACA in eye-











Figure 1.16 The structures of (A) N-acetylcysteine and (B) N-acetylcysteine amide 






1.3. EYE ANATOMY AND PHYSIOLOGY 
1.3.1. Eye Anatomy. The eye is made up of three layers of tissues. The 
outermost layer is composed of the cornea and sclera. The middle layer contains the 
choroid, ciliary body, pigmented epithelium, and iris. The light-sensitive retina is the 
innermost layer. The lens focuses an image of the visual world on the retina, which acts 
like film in a camera. The macula lies near the center of the retina and is responsible for 
high-resolution color vision. The fovea is a small depression at the center of the macula 
and enables the highest-resolution vision. Figure 1.17 shows a horizontal section of the 
right eye 
[45]
. Once the retina receives light focused by the lens, it converts the light into 
electrical signals and then sends these signals through the optic nerve to the brain. When 
the macula is damaged, the center of a visual image will be blurry or lost completely 
[46]
, 
which will affect a patient’s daily activities, such as driving, reading, and recognizing 
faces. 
 





1.3.2. Retina. Histologically, the retina has three layers that contain nerve cell 
bodies and two layers of synapses (Figure 1.18) 
[47]
. The three nerve cell body layers are 
the ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL). 
These layers are interconnected by two synapses, the inner plexiform layer (IPL) and the 
outer plexiform layer (OPL). The GCL contains the bodies of ganglion cells and 
displaced amacrine cells; the INL contains the bodies of bipolar, horizontal, and amacrine 
cells; and the ONL contains cell bodies of the rods and cones. The IPL functions as a 
relay station for the vertical-information-carrying nerve cells, the bipolar cells, to connect 
with ganglion cells. In the OPL, rods and cones synapse with both horizontal cells and 
bipolar cells. The retinal pigment epithelium (RPE) is a single layer of hexagonal cells 
and contains the pigment melanin. The RPE connects retinal cells and the choroid and 
forms a part of the blood-retinal barrier. Figure 1.19 shows a color fundus photograph of 
a normal macula and a cross-section of macular layers 
[48]
. 
1.4. AGE-RELATED MACULAR DEGENERATION 
1.4.1. What is AMD? Age-related macular degeneration (AMD) is the leading 
cause of irreversible blindness in the industrialized world, and the third-leading cause 
worldwide 
[49, 50]
. In the U.S, about 2.1 million people are affected by AMD, and the 
number of cases is projected to increase to 3.7 million by 2030 
[51, 52]
. Taking aging (the 
major risk factor) into consideration, the expected global prevalence of AMD is expected 
to be approximately 196 million by 2020, and rising to 288 million in 2040 
[53]
. The 
prevalence of AMD is close to that of invasive cancers and almost twice that of 
Alzheimer’s [54]. This creates an annual direct health care cost of $4.6 billion in the 
U.S.
[55]
. Unfortunately, patients with AMD lose quality of life because they require 






Figure 1.18  A cross-sectional diagram depicting the major structures of the eye is shown 
on the left, and an enlarged diagram of the neural retina, underlying the RPE, choroid, 





AMD is a degenerative condition that begins in Bruch’s membrane and 
progresses to involve the RPE and ultimately the overlying photoreceptors 
[57]
. The 
clinical hallmark of AMD is the presence of drusen. AMD is classified as dry (non-
exudative, affecting an estimated 85-90% of patients) or wet (exudative, affecting an 
estimated 10-15% of patients) clinically. The non-exudative disease is characterized by 
RPE death, or geographic atrophy. Attenuation of the overlying photoreceptors, which 
are located in the outer nuclear layer, follows the demise of the RPE. The distinguishing 
feature of wet AMD is choroidal neovascularization, followed by exudation and 





; however, this can be halted if a therapeutic intervention is initiated early enough 
during the course of the disease.  
Currently, there is no FDA-approved treatment for dry AMD. The only available 
treatment to slow the progression of visual loss in dry AMD includes vitamin and 
micronutrient supplementation, cessation of smoking, and dietary modification 
[60, 61]
.  
Figure 1.19A is a fundus photograph of the normal macula, and Figure 1.19B is a cross 
section of retina (after Haemotoxylin and Eosin staining) that shows the multilayer 
structure of the macula 
[48]
. Figure 1.20 compares the pathophysiological classification of 
age-related macular degeneration 
[57, 62]
. In early AMD, there are a few medium-sized soft 
drusen (63-124 microns in diameter) and retinal pigmentary abnormalities. In 
intermediate AMD, at least one large (≥ 125 microns in diameter) and more medium-
sized drusen are present, as well as geographic atrophy that does not involve the center of 
the macula. Advanced non-neovascular AMD is characterized by drusen and geographic 
atrophy that extends to the center of the macula. Advanced neovascular AMD is 
characterized by choroidal neovascularization and its consequences, including subretinal 
fluid, lipid deposition, hemorrhage, and retinal pigment epithelium (RPE) detachment. 
1.4.2. Risk Factors for AMD. AMD is a multifactorial disease. The risk factors 
include tobacco smoking, white race, genetics (complement factor H), and light exposure 
(expecially blue light). AMD is also associated with hypertension, atherosclerosis, fat-
rich diet, and obesity 
[63, 64]
. Age is the most significant risk factor for AMD, due to the 





Figure 1.19 A normal macula (a) Color fundus photograph of a normal left macula. (b) 
Multilayer structure of a macula (adapted from Handa J.T. 
[48]
). 
From top to bottom: NFL, nerve fiber layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PR, 




Figure 1.20 Fundus photographs and a cross section of H&E stain showing the 
histopathological features in different stages of age-related macular degeneration (AMD) 
(adapted and modified from Jager, R. D. et al. 
[57]
). 
The white arrow indicates the drusen and geographic atrophy; the black arrow indicates 





1.4.3. How Does Oxidative Stress Contribute to AMD? The RPE is a 
monolayer of cuboidal and columnar cells which regulate ion and metabolite transport, 
phagocytose photoreceptor outer segments (OS), and metabolize the retinol. These cells 
also form the outer blood-retinal barrier and thus maintain the extracellular matrix 
[65]
. 
This complex layer is subject to intense oxidative insult; therefore, oxidative stress plays 
an important role in the dysfunction of the RPE and other retinal cells in macular 
degeneration.  
This level of exogenous oxidative stress is potentiated by the relative paucity of 
antioxidants, such as GSH, in an aging retina. Light-induced peroxidation of shed 
photoreceptor outer segments, that contain polyunsaturated fatty acids (PUFAs), leads to 
the formation of toxic reactive oxygen species (ROS) and lipofuscin. Lipofuscin contains 
a fluorescent mixture of lipid-protein complexes, by-products of vitamin A (bisretinoids) 
metabolism, and lipid peroxidation products. Lipofuscin is cytotoxic and can activate 
complement and increase oxidative stress in RPE. Accumulation of ROS-laden lipofuscin 
granules, elevated local oxygen tension, high PUFA content, light exposure, and 
secondary photosensitizing agents that accumulate with aging create a highly oxidizing 
environment for the RPE 
[52]
. The peroxidation by-product of PUFAs, mainly is 
docosahexaenoic acid (DHA) to form carboxyethylpyrrole (CEP), can bind to protein. 
The CEP-protein adducts can further lead to activate complement and induce neo-
angiogenesis. Figure 1.21 shows the resources of oxidative stress and outline the key role 








Figure 1.21 Key role of oxidative stress in AMD pathogenesis (adapted from Nowak, J.Z. 
[66]




1.4.4. Treatment and the Results of Age-Related Eye Disease Study 
(AREDS). Treatment options for dry AMD are limited. Early AMD is asymptomatic and 
often goes untreated until more severe symptoms manifest as the disease progresses. For 
intermediate and late dry AMD, the only currently available treatments are aimed at 
slowing the progression to advanced AMD and include vitamin and micronutrient 





In prospective large trials, like the Age-Related Eye Disease Studies (AREDS and 
AREDS2), conducted by the U.S. National Eye Institute, a wide variety of nutrients were 
studied, including ω-3 fatty acids, antioxidants (β-carotene and vitamins C and E), 
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minerals (zinc and copper), and xanthophyll carotenoids (lutein and zeaxanthin) 
[67, 68]
. 
The first AREDS trial was performed in 1990, and results showed that a combination of 
vitamin C (500 mg/day), vitamin E (400 IU/day), β-carotene (25,000 IU)/day), zinc (zinc 
oxide, 80 mg/day), and copper (cupric oxide, 2 mg/day) can reduce the risk of late AMD 
by 25% 
[69]
. The follow-up ARDES2 study was initiated in 2006, for a period of over 5 
years, to evaluate the effects of adding lutein, zeaxanthin, and ω-3 fatty acids to the 
original AREDS formulation on progression to advanced AMD. A further modification 
of the original AREDS formulation was the elimination of β-carotene because of possible 
pro-oxidant activity that could increase lung cancer risk in smokers. The AREDS2 
formulas incorporated either lutein and zeaxanthin (10 mg/day and 2 mg/day) or DHA 
and EPA (350 mg/day and 650 mg/day) 
[70]
. Compared with results for participants 
treated with the original formulation (with β-carotene, but neither lutein nor zeaxanthin), 
those who were administered the AREDS2 formulation (with lutein and zeaxanthin but 
no β-carotene) had an 18% lower risk of progressing to advanced AMD (95% CI, 0.69-
0.96; P = 0.02) [68, 71]. 
Exudative AMD is characterized by choroidal neovascular membrane formation. 
The available treatments include anti-VEGF therapy (e.g., ranibizumab), macular thermal 
laser photocoagulation, and photodynamic therapy (PDT, e.g., Visudyne
®
) to minimize or 
block new blood vessels 
[72]
. For dry AMD, however, there is currently no FDA-approved 
treatment. Although numerous investigations of candidate treatments have been 
conducted, the results of these studies are inconclusive. Therefore, there is a dire need for 
an effective AMD treatment. An ideal therapeutic agent should be highly bioavailable, 
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non-toxic, easy to use, and economical. It should also limit oxidation, boost anti-
oxidative mechanisms, and even reverse existing damage. 
1.4.5. The Protective Effect of NACA in Eye-Related Research. For more 
than a decade, our research group has been investigating the use of thiol antioxidants, 
particularly N-acetylcysteine amide (NACA)
[73-75]
, in oxidative stress-related eye 
disorders such as cataracts and AMD 
[43, 76-80]
. The immortalized ARPE-19 cell line and 
primary cultures of RPE cells were used as in vitro models. ROS generation and lipid 
peroxidation induced by tert-butyl hydroperoxide (TBHP) were reversed by pretreatment 
with NACA. NACA also protected against TBHP-induced cell damage by increasing 
cellular levels of GSH, increasing antioxidant enzyme glutathione peroxidase (GPx) 
activity, and maintaining cellular integrity, as measured by transepithelial electrical 
resistance (TEER). In an animal model, phototoxicity-induced photoreceptor cell death 
and dysfunction were prevented by NACA 
[77]
. 
1.5. OTHER OXIDATIVE-STRESS RELATED EYE DISORDERS 
Oxidative stress and ROS are involved in the pathogenesis of numerous eye 
disorders 
[81, 82]
, especially in age-related cataract 
[83]
, age-related macular degeneration 
(AMD), open-angle glaucoma 
[84]
, and diabetic retinopathy 
[85, 86]
. They are also 
implicated in autoimmune uveitis and pseudoexofoliation syndrome (PEX). Important 
features of these diseases and the role of oxidative stress in each will be discussed briefly 
in the following section. Table 1.4 summarizes the major risk factors and role of 





Table 1.4 Summary of the risk factors of oxidative-stress related ocular diseases and the 
role of oxidative stress in pathogenesis of each 
Ocular Disorders   
-tissue affected 







































High fat diets 
Cataract surgery 






High oxygen tension 
High metabolic activity 
High energy light 
Photo-oxidative damage 



















































-outer segment of 
retina 




-  systemic disease in 
the anterior segment 
of eye  
 Age ↓GSH 
↑MDA in lens epithelial 
cell 
RPE, retinal pigment epithelium; NPDR, non-proliferative diabetic retinopathy; PDR, 
proliferative diabetic retinopathy; 4-HNE, 4-hydroxyl-2-nonenal; CEP, 
carboxyethylpyrrole; TM, trabecular meshwork. 
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1.5.1. Cataract. A cataract is the progressive opacification of the lens, resulting 
in blurred vision. Cataracts are the leading cause of blindness worldwide and account for 
42% of all blindness 
[90]
. While the primary cause of cataracts is age, they are also 
common in diabetes where superoxide levels in the mitochondria are elevated as a result 
of hyperglycemia 
[90]
. Increased serum MDA levels and decreased blood levels of 
enzymatic antioxidants SOD and GPx are also indicators of oxidative stress observed in 
cataract patients 
[91]. α-Crystallin, a major protein family in the lens, is responsible for the 
maintenance of lens transparency. It has been demonstrated that exposure to UV light 
induces cross-linking of α-, β- and γ-crystallins [87]. α-Crystallins can also act as 
chaperons against photodamage from UV light 
[92]
. Figure 1.22 shows how aging and 
diabetes affect the chaperone function of α-crystallins in cataract formation [92]. 
 
 
Figure 1.22 The possible molecular events affecting chaperone function of α‐crystallins 
during aging and diabetes and potential target points for modulation α‐crystallin 






1.5.2. Glaucoma. In this disease, fluid builds up in the anterior chamber of the 
eye, which increases intraocular pressure and results in retinal ganglion cell apoptosis and 
damage to the optic nerve. Glaucoma is the second most common cause of blindness 
worldwide 
[84]
. The trabecular meshwork (TM) has fewer antioxidant defenses than the 
cornea and iris, thus making it the most sensitive tissue to oxidative insult in the anterior 
chamber of the eye. There are three key pieces of evidence that suggest TM cells are 
subject to a highly oxidizing environment 
[82, 84]
. First, increased hydrogen peroxide 
(H2O2) measured in the aqueous humor outflow depletes glutathione 
[93]
. Secondly, the 
antioxidant potential in TM tissue from open-angle glaucoma patients was lower than that 
in controls 
[94]
. Finally, increased ROS levels (H2O2) have been shown to damage to 
mitochondrial DNA in the TM. Oxidative stress, occurring not only in the TM but also in 
retinal cells, appears to be involved in the neuronal cell degeneration affecting the optic 
nerve in open-angle glaucoma 
[82, 95]
. The oxidation in the TM involved in the 
pathogenesis of open-angle glaucoma is shown in Figure 1.23. 
 
 
Figure 1.23 Key role of oxidative stress in glaucoma pathogenesis. 
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1.5.3. Diabetic Retinopathy (DM). Diabetic retinopathy is one of the most 
common microvascular complications in diabetes mellitus (DM) patients and is the 
leading cause of blindness and visual dysfunction in working-age populations 
[96, 97]
. 
Hyperglycemia induces ROS production in mitochondria, leading to increased levels of 
reactive oxygen metabolites in type 2 DM patients 
[85]
. Hyperglycemia upregulates the 
polyol pathway (also called the sorbitol-aldose reductase pathway), resulting in decreased 
NADPH available for GR-catalyzed regeneration of GSH from GSSG 
[86]
. 
Hyperglycemia also activates PKC and contributes to ROS formation. Figure 1.24 shows 






Figure 1.24 Relationship between hyperglycemia, oxidative stress, and pathways 






1.5.4. Retinitis Pigmentosa (RP). RP, also known as rod-cone dystrophy, is an 
inherited eye disorder that causes photoreceptor breakdown and retinal degeneration. 
Human ONL is composed of 95% rods and 5% cones. Oxidative damage is a major 
contributor to cone cell death. Oxygen utilization is greatly reduced after rods die, which 
eventually disturbs the oxygen balance in the outer retina. High oxygen tension and 
NADPH oxidase activation cause superoxide radical production in both mitochondria and 
cytoplasm in cones 
[98, 99]
. 
1.5.5. Autoimmune Uveitis. The uvea is the layer located between the sclera 
and the retina that includes the iris, ciliary body, and choroid. Inflammation during 
uveitis is strongly correlated with ROS generation 
[100]
. Oxidative stress caused by DNA 
damage in photoreceptor mitochondria likely initiates the pathological effects. Figure 
1.25 shows the role of oxidative stress in autoimmune uveitis as well as the effect of 
antioxidants in preventing uveitis complications 
[100]
. 
1.5.6. Pseudoexfoliation Syndrome (PEX). PEX is an age-related fibrillopathy 
of the eye. It is characterized by the accumulation of granular material on the anterior 
segment structures of the eye and is associated with glaucoma and cataract surgery 
complications 
[81, 101]
. Decreased GSH levels and increased lipid peroxidation by-product 
malondialdehyde (MDA) levels were found in the lens epithelial cells of PEX patients, 

















2. EXPERIMENTAL DESIGN 
Since oxidative stress is strongly implicated in the pathogenesis of AMD, we 
hypothesized that N-acetylcysteine amide (NACA), a novel thiol antioxidant, would 
impede the progression of oxidative stress-induced retinal degeneration. We designed an 
in vitro and an in vivo model to investigate the effectiveness of NACA in preventing 
retinal pigment epithelial cell and retinal cell damage. 
 In an in vitro model, we tested the ability of NACA to prevent oxidative stress 
induced by tert-butyl hydroperoxide in primary human retinal pigment epithelial cells 
(HRPEpiC) (Figure 2.1). 
 
 
Figure 2.1 The experimental hypothesis of NACA’s role in defending RPE cells against 
oxidative stress in a cell model. 
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In an animal model, we investigated the effectiveness of NACA eye drops in 
preventing and/or delaying photoreceptor loss and maintaining visual potential in sodium 




Figure 2.2 The experimental hypothesis of NACA’s role in defending against sodium 
iodate-induced retinal degeneration in an animal model. 
 
 
Sodium iodate was first used in 1941 to selectively induce retinal degeneration in 
rabbits. Systematic delivery of NaIO3, a stable oxidizing agent, is an effective way to 
induce retinal degeneration, with loss of retinal function followed by local morphological 
changes in RPE cells and photoreceptors, and significant ONL thinning.  
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To study the effectiveness of NACA eye drops in preventing retinal degeneration, we 
utilized an animal model with sodium iodate-treated C57BL/6 mice. The details of the 









3. MATERIALS & METHODS 
3.1. MATERIALS 
N-acetylcysteine amide (NACA) was provided by Dr. Glenn Goldstein (David 
Pharmaceuticals, New York, NY, USA). C57BL/6 mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). Other chemicals were ordered from Sigma (St. 
Louis, MO, USA), unless otherwise indicated. 
Human retinal pigment epithelial cells (HRPEpiC, CAT # 6540) were purchased 
from ScienCell Research Laboratories (Carlsbad, CA, USA). HRPEpiC were grown as 
suggested by ScienCell, and all experiments were performed during passages 4 and 5. 
3.2. CELL CULTURE CONDITIONS 
HRPEpiC were grown in complete media and divided in to four groups (control, 
NACA, TBHP, and NACA+TBHP). Cells were pretreated with 2 mM NACA (in NACA 
and NACA+TBHP groups) or serum-free media (in control and TBHP groups). After 4 
hours of incubation, the media was removed, and cells were washed with PBS and then 
dosed with 0.5 mM TBHP (in TBHP and NACA+TBHP groups) or serum free media 
(control and NACA groups) for 3 hours. For apoptosis assays, an alternative NACA and 
TBHP dosing protocol was used in addition to the one described above. This involved 
pretreatment with NACA for 1 hour (in NACA and NACA+TBHP groups) prior to 
TBHP exposure and addition of NACA (in NACA and NACA+TBHP groups) to the 
media for an additional 3 hours while TBHP was applied (i.e., cells were co-exposed to 
TBHP and NACA for 3 hours).  
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3.3. CELL VIABILITY ASSAY 
Calcein-AM is a cell-permeant dye that can be used to determine cell viability in 
most eukaryotic cells. In living cells, the non-fluorescent Calcein-AM is converted to 
green-fluorescent Calcein after acetoxymethyl ester hydrolysis by intracellular esterases. 
The structure of  Calcein-AM and its staining mechanism is illustrated in Figure 3.1
[103]
.  
Each well of 96-well plate contained 1×10
4
 cells were grown in complete media 
for 24 hours before further dosing. After cells were rinsed with 1X PBS (37 °C), cells 
were treated as indicated in the experimental design. Each well of cells was replaced with 
100 μL of 2 μM Calcein-AM (Biotium Inc., CA, USA) in 1X phosphate buffered saline 
(PBS), and cells were incubated for 30 min before measuring the fluorescence by a plate 













3.4. INTRACELLULAR REACTIVE OXYGEN SPECIES (ROS) 
MEASUREMENT  
Cellular ROS accumulation was measured using 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, Molecular Probes, 
Life Technologies) 
[104-106]
. CM-H2DCFDA is a chloromethyl derivative of H2DCFDA 
(2′,7′-dichlorodihydrofluorescein diacetate; molecular formula: C24H16Cl2O7) and 
exhibits better retention in live cells than H2DCFDA. CM-H2DCFDA passively diffuses 
into cells, where its acetate groups are cleaved by intracellular esterases, and its thiol-
reactive chloromethyl group reacts with intracellular glutathione and other thiols. 
Subsequent oxidation yields a fluorescent adduct that is trapped inside the cell and can 
therefore be detected for extended periods of time, making CM-H2DCFDA a valuable 
tool for ROS quantification during a longer-term experimental design. The structure of 
CM-H2DCFDA and the mechanism of ROS measurement are illustrated in Figure 3.2. 
Each well of 96-well plate contained 1×10
4
 cells were grown with complete 
media for 24 hours. CM-H2DCFDA was freshly dissolved in dimethyl sulfoxide (DMSO) 
to make 10 mM stock solution, then further diluted in 1X PBS to make working solution 
and kept from light exposure. After the cells were rinsed with 1X PBS (37 °C), 100 μL of 
10 μM CM-H2DCFDA in 1X PBS (37 °C) were added to each well, and then plates were 
placed back to incubator for another 30 min. Each well was rinsed carefully with 1X PBS 
to remove extra CM-H2DCFDA after incubation. Cells were dosed with NACA and/or 
TBHP in 100 μL of serum-free, phenol red-free media according to the experimental 
design. Fluorescence was measured after treatment by a plate reader (λex = 485 nm and 





Figure 3.2 The measurement of ROS by CM-H2DCFDA. 
 
 
3.5. QUANTIFICATION OF INTRACELLULAR GLUTATHIONE (GSH) AND 
CYSTEINE LEVELS. 
GSH is the primary endogenous antioxidant responsible for redox homeostasis in 
endothelial cells. Cells were grown at a density of 1.2×10
6
 cells per 10-cm plate for 24 
hours before further treatment. Cell pellets were homogenized in serine borate buffer (pH 
= 7.5). Supernatant fractions were collected after centrifugation at 1000 xg at 4 °C for 10 
min. GSH was separated and quantified by HPLC with fluorescence detection (Finnigan 
Surveyor FL Plus, Thermo Scientific, USA) after derivatization of cell homogenates with 
N-(1-pyrenyl) maleimide (NPM) (Figure 3.3) 
[107-109]
. The mobile phase gradient program 
used for analysis of cysteine and GSH is shown in Table 3.1. 
For derivatization, retinas were homogenized in 230 µL of serine borate buffer 
(pH = 7.5). 50 µL of retina homogenate were mixed with 25 µL of serine borate buffer, 
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and 225 µL of NPM was added to derivatize at room temperature for 5 min. Finally, 3 µL 
of 2 N HCl were added to quench the reaction. Representative separation of a mixed thiol 
standards and a retina sample by HPLC are shown in Figures 3.4 and 3.5. GSH level is 









Table 3.1 Gradient program of mobile phase used in the HPLC separation 
Time 
(min) 
Mobile phase A 
(%) 




0.0 100  0.7 
6.0 100  0.7 
6.1  100 1 
20.0  100 1 
20.1 100  0.7 
25 100  0.7 
The mobile phase A was composed of 0.05% acetic acid in 70:30 acetonitrile–
HPLC-H2O (vol : vol) in 1 liter of mobile phase. 
The mobile phase B was composed of 0.1% o-phosphoric acid and 0.1% acetic 




Figure 3.4 The above HPLC chromatogram showing the separation of a derivatized 









3.6. GLUTATHIONE REDUCTASE (GR) ACTIVITY ASSAY.  
Glutathione reductase (GR, EC 1.6.4.2) catalyzes the reduction of glutathione 
disulfide (GSSG) to GSH. This assay is based on the reduction of GSSG by NADPH in 
the presence of the enzyme. Cells were homogenized in 250 μL of 50 mM Tris-HCl (pH 
= 7.5) containing 1 mM EDTA. After centrifugation at 1000 xg for 15 min, the 
supernatant fractions were isolated. NADPH, which absorbs light at 340 nm, was added 
to each sample. The rate of its oxidation to NADP
+
 by GR as GSSG is reduced to 2 GSH 








800 µL of diluted supernatant + 40 µL of 25 mM GSSG + 160 µL of 1.25 mM NADPH 
(Proportion of supernatant should be increased if the rate of reduction in NADPH 
absorbance, [-ΔA]/min is less than 30 mAbs/min). 
 
GR activity calculation step by step: 
The molar extinction coefficient ε for NADPH at 340 nm is 6220 M-1cm-1. The activity of 
GR can be calculated according to the Beer-Lambert law as follows: 
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Given: ε = 6220 M-1cm-1 when the path length = 1 cm; 
ε = 6.22 x 10-3 (nmol/mL)-1; 
1 mU = 1 nmol/min (i.e., 1 mU GR reduces 1 nmol NADPH per min); 
Then: mU/mL = (ΔA340/min)/ε, or mU/mL = [A340/min]/[6.22 x 10
-3
 mL/nmol]; 
 mU/mg = (mU/mL)/(mg/mL protein) 
GR activity is then reported in units of mU/mg protein. 
 
3.7. QUANTIFICATION OF TOTAL PROTEIN 
Protein levels of the cell homogenates were measured by the Bradford method 
[112]
 (BioRad Laboratories, Inc., CA, USA) and BCA protein assay 
[113]
  (ThermoFisher 
Scientific, NY, USA). Bovine serum albumin was used as the protein standard. The 
protein concentration is reported in units of mg/mL protein. 
The Bradford protein assay, which was performed using Coomassie
® 
Brilliant 
Blue G-250, was used for total protein concentrations between 5 mg/mL to 50 mg/mL. 
After 20 μL of the protein was mixed with 1 mL of Coomassie® Brilliant Blue G-250 
solution, the absorbance shifted from 465 nm to 595 nm when the protein was bound to 
the dye. 
The bicinchoninic acid assay (BCA assay) was used for total protein 
quantification especially when samples with protein concentrations between 0.5 µg/mL to 




 by protein in an alkaline 
solution (Step 1 in Figure 3.6), and formed a purple-colored BCA-Cu
+
 complex that 














3.8. DEXTRAN PERMEABILITY AND TRANSEPITHELIAL ELECTRICAL 
RESISTANCE (TEER) MEASUREMENT 
12-mm Transwell® (Product #3401) inserts were coated with poly-L-lysine for 1 
hour prior to seeding with 0.5 mL of cell suspension at 1×10
6
 cells/mL. Each well 
contained 1.5 mL of media, and cell growth was maintained for 5 days without disturbing 
the monolayer (Figure 3.7). Cells were treated with NACA and/or TBHP according to the 
experimental design. After an appropriate time, the treatment media in the insert was 
removed and replaced with 250 μL of serum-free, phenol red-free media. The insert was 
then relocated to a new plate containing 1.5 mL of fresh serum-free, phenol red-free 
media. Fluorescently labelled dextrans (FD4, 1 mg/mL in media, Sigma) were 
administered apically onto the insert after dosing. Fluorescence was read after 30 min (λex 
= 485 nm and λem = 530 nm) (FLUOstar Omega, BMG Labtech, Cary, NC, USA). The 
inserts containing the monolayer were then transferred to new wells with 500 μL of 
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serum-free phenol, red-free media and used for TEER measurement. TEER readings 
were recorded by an EVOM voltohmmeter (World Precision Instruments, Sarasota, FL, 








3.9. FLOW CYTOMETRY QUANTIFICATION OF APOPTOTIC CELLS 
Cell suspension contained 6.5×10
5
 cells were grown in each of 6-cm plates and 
dosed as described by the experimental design. To conduct the apoptosis assay, 
trypsinized cells were re-suspended in 100 μL of 1X binding buffer containing 5 μL of 7-
AAD and 5 μL of annexin V-FITC (BD Biosciences, San Jose, CA, USA). Cells were 
incubated for 15 min at room temperature in the dark, followed by addition of 250 μL of 
binding buffer. The cells were then analyzed using a Cell Lab Quanta SC flow cytometer 
(Beckman Coulter, Fullerton, CA, USA). 
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3.10. ANIMAL MODEL AND EXPERIMENTAL DESIGN 
Seven-week-old male C57BL/6 mice were received and housed in a temperature- 
and humidity-controlled (about 22 °C and 55%, respectively) animal facility, with a 12-
hour light and dark cycle. The animals had free access to rodent chow and water; they 
were acclimatized for 1 week before experiments were performed. All animal procedures 
conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by the Institutional Animal Care and Use Committee of 
Missouri University of Science and Technology. 
Eight-week-old C57BL/6 mice received 0.1% NACA eye drops (in 25 mM 
phosphate buffer, pH 7.4) twice a day, on every other day for 4 weeks. After dosing with 
NACA for 4 weeks, mice received one intraperitoneal (IP) injection of 75 mg/kg NaIO3, 
and then eye drops were continued for another week. 
On the final day of the experiment, the mice were anesthetized by an IP injection 
of ketamine (120 mg/kg) and xylazine (16 mg/kg) and cervical dislocation was used for 
the secondary euthanasia method. Retinas were removed under a dissecting microscope 
and immediately placed in liquid nitrogen immediately for further analysis. 
3.11. ELECTRORETINOGRAPHY (ERG) 
After adaptation in the dark for 10-12 hours, scotopic and photopic ERG were 
recorded in mice under anesthesia induced by isoflurane (Butler Schein, Dublin OH) 
(2.25% for induction and 1.25% maintenance). Proparacaine hydrochloride ophthalmic 
solution and tropicamide (0.5%, Akorn Inc, IL, USA) were used for the topical anesthetic 
and mydriatic, respectively. The recording electrode was placed in a drop of 
methylcellulose on the surface of the cornea, a reference electrode was placed 
subdermally at the vertex of the skull, and a ground electrode was placed subdermally at 
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the base of the tail (Figure 3.8). Scotopic and photopic ERGs 
[115, 116]
 were recorded using 
an HMsERG machine (OcuScience, Henderson, NV, USA). ERG procedures started with 
a scotopic intensity series from -3 to 1 log (cd∙s/m2). Photopic ERGs were recorded after 
light adaption (10000 mcd∙s/m2) for 5 min (mcd: millicandelas). The scotopic and 
photopic view program is illustrated in Figure 3.9. Signals obtained from corneal surfaces 
were amplified, digitized, and averaged using ERG View 2.5 software (Retvet Corp 




Figure 3.8 More pictures in conducting electroretinography. (A) The corneal electrode is 
placed between contact lenses and the cornea; (B) The placements of corneal electrode 
(red), skin electrode (green), and mask to introduce isoflurane; (C) and (D) The 





Figure 3.9 The program settings for the scotopic and photopic view in an ERG recording. 
 
 
The ERG is a recording of a light-elicited diffuse electrical responses developed 
by cells within the retina 
[117]
. Four different waveforms (a-wave, b-wave, c-wave and d-
wave) may be observed, depending on the ERG program. The first negative peak was the 
a-wave, which was followed by a large, positive b-wave and a slower, positive c-wave. 
After termination of the stimulus, a d-wave developed. Figure 3.10 shows where the 
major components of the ERG originate. The ERG a-wave (called the “late receptor 
potential”) originated from the photoreceptors,  and the b-wave originated from the inner 
Scotopic/Photopic Subset 













Test 1 -3 3 4 30 90 90
Delay 30 120
Test 2 -2 30 4 30 90 210
Delay 30 240
Test 3 -1 300 4 30 90 330 rod only
Delay 30 360
Test 4 0 3000 4 30 90 450 mix
Delay 30 480
Test 5 1 30000 4 30 90 570
Background Light Adaptation 10000 300 870
Test 6 -0.25 2000 32 0.5 16 886
Delay 2 888
Test 7 -0.1 2500 32 0.5 16 904
Delay 2 906
Test 8 0 3000 32 0.5 16 922
Delay 2 924
Test 9 0.125 3500 32 0.5 16 940
Delay 2 942
Test 10 0.25 4000 32 0.5 16 958
Delay 2 960
Test 11 0.37 4500 32 0.5 16 976
Delay 2 978
Test 12 5000 32 0.5 16 994 cone only
Delay 2 996
Test 13 0.5 10000 32 0.5 16 1012
Delay 2 1014
Flicker Test 14 0 3000 128 0.033 2 1016
Flicker Test 15 0.5 10000 128 0.033 2 1018




retinal cells that are post-synaptic to the photoreceptors (Figure 3.10) 
[118]
. The a-wave 
and b-wave represented the health of the outer and inner retina, respectively. Analysis of 
the ERG waveforms required measurement of the amplitude and the implicit time of each 
wave (Figure 3.11) 
[118]
. In the ERG program used for the investigations described here, 
only the a-wave and b-wave were recorded and analyzed. 
 
 
Figure 3.10 Diagram of the retina showing where the major components of the ERG 







Figure 3.11 Electroretinogram (A) ERG waveform and (B) amplitude and implicit time 
measurement of the ERG waveform (adapted from Creel, D.J. [118]). 
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3.12. HEMATOXYLIN AND EOSIN (H&E) STAINING 
Eyes were enucleated and fixed in 4% paraformaldehyde overnight. Briefly, the 
eyes were then embedded in paraffin, and serial 5-μm of sagittal sections of the whole 
eye were cut through the cornea to the optic nerve. Paraffin-embedded serial sections of 
the retina were deparaffinized with xylene and absolute ethanol, rehydrated with distilled 
water, stained with hematoxylin solution, and counterstained with eosin. 
3.13. OUTER NUCLEAR LAYER (ONL) THICKNESS MEASUREMENT 
In each fixed and H&E-stained eye (n = 3 mice), the ONL thickness was 
measured at 40-μm intervals across 400-µm sections of the parafoveal area located 500 
µm from the optic nerve head. Images were analyzed at 20X objective magnification 
using ImageJ image processing software (Version 1.49, NIH). For every group, ONL 
thickness at each interval was averaged, and statistical analysis was performed. 
3.14. 4-HYDROXYNONENAL (4-HNE) IMMUNOHISTOCHEMISTRY 
STAINING AND QUANTIFICATION 
Briefly, serial sections adjacent to those designated for H&E staining were taken 
from paraffin-embedded eyes (n = 3 mice). Sections were deparaffinized, rehydrated, 
blocked, and incubated overnight at 4°C with an anti-4-HNE antibody (1:100 dilution; 
Abcam 46545, MA, USA) using 3,3'-diaminobenzidine (DAB) as the chromogen (which 
indicates the presence of 4-HNE as a dark brown stain) and hematoxylin as the 
counterstain. Images were examined at 100X objective magnification for quantification 
of 4-HNE levels, using ImageJ to determine the proportion of dark brown area to the total 
image area in the ONL. 
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3.15. SDS-PAGE AND WESTERN BLOT FOR PTEN AND PHOSPHO-PTEN (P-
PTEN) ANALYSIS. 
Protein levels of cell homogenates were measured using the bicinchoninic acid 
(BCA) protein assay. 25-μg of the protein samples (n = 3 mice) were separated in 
NuPage 12% Bis-Tris gels (Life Technologies, Grand Island, NY). Anti-PTEN (Cat # 
9552) and anti-p-PTEN (Ser380/Thr382/383, Cat # 9554) (1:1000 dilutions; Cell 
Signaling, MA, USA) were used as the first antibodies, and GAPDH (1:1000 dilution; 
Cell Signaling) was used as the dominant housekeeping gene. SuperSignal 
Chemiluminescent substrate was used to visualize PTEN bands. The membrane was 
stripped after PTEN measurement, and the procedure was repeated for anti-p-PTEN. 
SuperSignal West Pico Chemiluminescent substrate and Restore Western blot stripping 
buffer were obtained from Thermo Scientific. 
3.16. STATISTICAL ANALYSIS 
All values are reported as mean ± SD. Statistical analysis was performed using 
GraphPad Prism 5 software (GraphPad, San Diego, CA, USA). Statistical significance 
was determined by one-way analysis of variance (ANOVA), followed by Tukey’s 
multiple comparison tests. Values of P < 0.05 were considered significant. Each 
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Background: Age-related macular degeneration (AMD) is a leading cause of blindness 
in the United States among adults age 60 and older. While oxidative stress is implicated 
in the pathogenesis of AMD, dietary antioxidants have been shown to delay AMD 
progression in clinical studies. We hypothesized that N-acetylcysteine amide (NACA), a 
thiol antioxidant, would protect retinal pigment epithelium and impede progression of 
retinal degeneration. 
Methods: tert-Butyl hydroperoxide (TBHP) was used to induce oxidative stress in cell 
cultures. The goal was to evaluate the efficacy of NACA in an in vitro model of AMD in 
primary human retinal pigment epithelial cells (HRPEpiC). 
Results: Our data indicates that TBHP generated reactive oxygen species (ROS), which 
reduced cell viability, depleted glutathione (GSH) levels, and compromised glutathione 
reductase (GR) activity. Pretreatment with NACA significantly reduced ROS generation, 
restored GSH levels and GR activity, and recovered transepithelial electrical resistance. 
Pretreatment with NACA did not decrease the number of dying cells, as determined by 
flow cytometry analysis. However, survival was significantly improved when cells were 
co-exposed to NACA and TBHP after a shortened pretreatment period. 
Conclusions: Our data suggest that pretreatment with NACA reduces sublethal but not 
lethal effects of TBHP in HRPEpiC. NACA significantly improved cell survival when 
administered prior to and during oxidative damage similar to that observed in the 
development of dry AMD. These results indicate that continuation of a thiol antioxidant 
regimen for treatment of AMD is beneficial throughout the course of the disease, and that 




Age-related macular degeneration (AMD) accounts for 8.7% of blindness 
worldwide, and is a leading cause of blindness in the United States among adults age 60 
and older 
[1-3]
. Globally, about 1 in 32 visual impairments and 1 in 15 cases of blindness 
are due to macular disease 
[4]
. Dry AMD is a degenerative condition that begins in 
Bruch’s membrane and progresses to the retinal pigment epithelium (RPE) and the 
overlying photoreceptors resulting in loss of central vision. The RPE is a single layer of 
pigment cells lying between the photoreceptors and choriocapillaris. Its functions include 
light absorption, epithelial transport, phagocytosis, secretion, and immune modulation. 
All of these functions are important for maintaining and supporting the photoreceptors. A 
high blood flow rate and high O2 saturation in the choriocapillaris render the RPE more 
exposed to oxidative stress 
[5]
. Oxidative stress seems to play a major role in the 
pathogenesis of dry AMD and retinal degeneration, although the pathophysiology of dry 
AMD is complex 
[5, 6]
. The macula is subject to increased levels of photo-oxidative stress 
because of its elevated metabolic rate and high proportion of polyunsaturated fatty acids, 
which are highly susceptible to lipid peroxidation. As the RPE cells of the macula age, 
the oxidation of lipids and other cellular components result in an accumulation of 
indigestible lipofuscin in the lysosomes. The accumulation of lipofuscin granules closely 
parallels drusen formation in time and distribution in the retina. Oxidative damage to the 
mitochondrial DNA in RPE cells has also been implicated in the development of AMD. 
Levels of antioxidants in retinal tissue, glutathione (GSH) in particular, decrease with 





Endogenous antioxidants, such as GSH, cannot be directly replaced. Instead, 
compounds that can easily enter cells and increase intracellular antioxidant levels are 
preferred. Dietary antioxidants have been shown to slow the progression of retinal 
degeneration and halt progression of AMD in human clinical trials.
[9, 10]
 GSH and its 
amino acid precursors protect RPE cells from oxidative injury and oxidant-induced 
apoptosis in vitro. N-acetylcysteine amide (NACA), a GSH prodrug, is a promising 
candidate for use as an antioxidant-based treatment for AMD. It has demonstrated 
efficacy in numerous in vitro and animal models of other oxidative stress-related 
conditions, including drug-induced RPE damage and cataracts 
[11-15]
. Our lab has 
demonstrated that NACA prevented retinal degeneration in vitro and in animal models 
[14]
. The immortalized ARPE-19 cell line was used as an in vitro model because primary 
human RPE cells were not available at the time. ROS generation and lipid peroxidation 
induced by tert-butyl hydroperoxide (TBHP) were reversed by pretreatment with NACA. 
NACA also protected against TBHP-induced cell damage by increasing cellular levels of 
GSH, and maintaining cellular integrity, as measured by transepithelial electrical 
resistance (TEER). In an animal model, phototoxicity-induced photoreceptor cell death 
and photoreceptor dysfunction were prevented by NACA 
[14]
. 
The experiments reported here utilized primary cultures of human retinal pigment 
epithelial cells (HRPEpiC), the best available in vitro model for studying RPE-related 
disorders. Because we attempted to mimic a human disease and provide a solution using 
a “disease-in-the-dish” model, choosing the most representative cell model was critical. 
Thus, we decided to determine whether the beneficial effects of NACA observed in 
ARPE-19 cells could also be observed in the HRPEpiC. Our goals were to investigate the 
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following: (1) the sub-lethal and lethal effects of TBHP in HRPEpiC and (2) the 
protective effects of NACA pretreatment against TBHP-induced oxidative damage. 
Sublethal effects included changes in redox status (ROS generation, GSH levels and GR 
activity) and monolayer integrity (TEER and dextran permeability). Lethal effects were 
determined with cell viability and apoptosis assays. 
 
 
2. MATERIALS AND METHODS 
2.1. MATERIALS  
N-acetylcysteine amide (NACA) was provided by Dr. Glenn Goldstein (David 
Pharmaceuticals, New York, NY, USA). Human retinal pigment epithelial cells 
(HRPEpiC) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA). 
Other chemicals were ordered from Sigma (St. Louis, MO, USA), unless otherwise 
indicated. 
2.2. HRPEPIC CULTURE AND EXPERIMENTAL DESIGN 
HRPEpiC were grown in complete media and divided in to four groups (control, 
NACA, TBHP and NACA+TBHP). Cells were pretreated with 2 mM NACA (in NACA 
and NACA+TBHP groups) or serum-free media (in control and TBHP groups). After 4 
hours incubation, the media was removed, and followed by dosing with 0.5 mM TBHP 
for 3 hours. For apoptosis assays, an alternative NACA and TBHP dosing protocol was 
used in addition to the one described above. This involved pretreatment with NACA for 1 
h prior to TBHP exposure and the addition of NACA for another 3 hours (i.e., the 
NACA+TBHP group cells were co-exposed to TBHP and NACA for 3 hours). 
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2.3. CELL VIABILITY ASSAY  
Cell suspension contained 1×10
4
 cells per well were seeded in a 96-well plate for 
24 hours before further dosing. After cells were treated as indicated in the experimental 
design, 2 μM Calcein-AM (Biotium Inc., CA) were added to each well, and cells were 
incubated for 30 min before measuring the fluorescence by a plate reader (λex = 485 nm 
and λem = 530 nm) (FLUOstar Omega, BMG Labtech). 
2.4. INTRACELLULAR ROS MEASUREMENT 
10 μM of CM-H2DCFDA (Molecular Probes, Life Technologies) were loaded 
prior to dosing according to the experimental design. Fluorescence was measured after 
treatment (λex = 485 nm and λem = 530 nm). 
2.5. QUANTIFICATION OF INTRACELLULAR GLUTATHIONE (GSH) 
LEVELS  
Cells were grown at a density of 1.2×10
6
 in a 10-cm plate for 24 h before further 
treatment. GSH was separated and quantified by HPLC with fluorescence detection 
(Finnigan Surveyor FL Plus, Thermo Scientific) after derivatization of cell homogenates 
with N-(1-pyrenyl)maleimide (NPM) 
[16]
. 
2.6. GLUTATHIONE REDUCTASE (GR) ACTIVITY ASSAY 
Cells were homogenized in 250 μl of 50 mM Tris-HCl (pH = 7.5) containing 1 
mM EDTA. NADPH, which absorbs light at 340 nm, was added to each sample. The rate 
of its oxidation to NADP
+
 by GR as GSSG is reduced to 2 GSH can be determined from 
the resulting decrease in absorbance at this wavelength over time 
[17]
. 
2.7. DETERMINATION OF PROTEIN  
Protein levels of the cell homogenates were measured by the Bradford method 
(BioRad Laboratories, Inc., CA). Bovine serum albumin was used as the protein standard. 
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2.8. DEXTRAN PERMEABILITY AND TRANSEPITHELIAL ELECTRICAL 
RESISTANCE (TEER) MEASUREMENT 
12-mm Transwell inserts were coated with poly-L-lysine for 1 h prior to seeding 
0.5 ml at 1×10
6
 cells/ml. Cell growth was maintained for 5 days without disturbing the 
monolayer. Fluorescently labelled dextrans (FD4, 1 mg/ml) were administered apically 
onto the insert after dosing. Fluorescence was read after 30 min (λex =485 nm and λem = 
530 nm). The inserts containing the monolayer were then transferred to a new well with 
serum-free phenol red-free media and used for TEER measurement with an EVOM 
voltohmmeter (World Precision Instrument, Sarasota, FL, USA) to assess the integrity of 
the HRPEpiC monolayer. 
2.9. FLOW CYTOMETRY QUANTIFICATION OF APOPTOTIC CELLS 
Cells were grown in 6-cm plates and dosed as described by the experiment design. 
Trypsinized cells were re-suspended in binding buffer containing 7-AAD and annexin V-
FITC (BD Biosciences, San Jose, CA, USA). Cells were incubated for 15 minutes at 
room temperature in the dark then analyzed by Cell Lab Quanta SC flow cytometry 
(Beckman Coulter, Fullerton, CA, USA). 
2.10. STATISTICAL ANALYSIS  
All values were reported as mean ± SD (n = 3 to 10). Statistical analysis was 
performed using GraphPad Prism 5 software (GraphPad, San Diego, CA, USA). 
Statistical significance was determined by one-way analysis of variance (ANOVA), 
followed by Tukey’s multiple comparison tests.  #, ##, and ### represent P < 0.05, 0.01 
and 0.001, respectively, as compared to control; *, **, and ***, which represent P < 0.05, 





3.1. TBHP INCREASED INTRACELLULAR ROS LEVELS IN HRPEPIC, AND 
NACA PREVENTED ROS GENERATION 
To investigate ROS generation in response to TBHP treatment, ROS levels were 
measured after exposing cells to TBHP for 3 hours. TBHP induced ROS generation in a 
dose-dependent manner (Figure 1A). ROS levels in TBHP-treated cells were 177% of 
those observed in the control group (P < 0.001). Pretreatment with NACA decreased 
ROS levels to 126% of those observed in the control group (P < 0.001 compared to 




Figure 1. Intracellular ROS levels were measured using DCF fluorescence.  
(A) TBHP induced ROS generation in a dose-dependent manner. (B) NACA prevented 





3.2. DOSE-DEPENDENT GSH DEPLETION BY TBHP AND PREVENTION BY 
PRETREATMENT WITH NACA 
To elucidate the consequences of elevated ROS in HRPEpiC, GSH levels were 
measured after treatment for 3 hours with various concentrations of the TBHP. TBHP 
decreased cellular GSH levels in a dose-dependent manner: the average GSH levels in 
cells treated with 0, 0.5, 1, 25 and 50 mM of TBHP were 33.4 ± 5.0, 25.1 ± 1.5, 18.9 ± 
0.7, 8.8 ± 1.9 and 6.2 ± 1.3 nmol/mg protein, respectively (P < 0.001 compared to 
control) (Figure 2A). The protective effect of NACA on GSH depletion in cells treated 
with TBHP was also investigated (Figure 2B). GSH is the major antioxidant in a cell and 
NACA is a GSH precursor, providing cysteine for GSH synthesis. The average GSH 
level in the control group was 31.7 ± 2.3 nmol/mg protein. The GSH level was increased 
after NACA incubation (55.1 ± 7.3 nmol/mg protein, P < 0.001 compared to control). 
The average GSH level of  the TBHP group was 25.1 ± 1.5 nmol/mg protein (P < 0.01 
compared to control), but the NACA+TBHP group had an average GSH level of 30.5 ± 
2.5 nmol/mg protein (P < 0.05, compared to the TBHP group). 
 
 
Figure 2. Intracellular GSH levels in HRPEpiC. 
(A) TBHP depleted GSH levels in a dose-dependent manner. (B) NACA dramatically 
increased intracellular GSH levels and prevented GSH depletion by TBHP.  
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3.3. PRESERVATION OF GLUTATHIONE REDUCTASE ACTIVITY BY 
PRETREATMENT WITH NACA  
Glutathione reductase (GR), an enzyme that reduces glutathione disulfide to GSH, 
is important in restoring intracellular levels of GSH. GR activity was reduced in the 
TBHP group (33.5 ± 3.2 versus 21.9 ± 2.2 mU/mg protein in the control group; P < 0.01) 
(Figure 3). NACA-pretreated cells exhibited increased GR activity (33.5 ± 5.2 mU/mg 




Figure 3. Preservation of glutathione reductase activity by NACA. 
 
 
3.4. EFFECTS OF OXIDATIVE STRESS ON HRPEPIC MONOLAYER 
PARACELLULAR PERMEABILITY AND CONTRIBUTION OF NACA TO 
MONOLAYER FUNCTIONAL HOMEOSTASIS  
RPE paracellular permeability was assessed in a HRPEpiC grown on a 
polycarbonate insert, which formed a monolayer similar to that of the blood-retina barrier 
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in vivo. Transepithelial electrical resistance (TEER) was used as a measure of 
paracellular permeability to ions, where lower electrical resistance was evidence of 
decreased membrane integrity of a  HRPEpiC in the monolayer. Permeability to non-
ionic molecules was determined based on the amount of dextran that passed through the 
monolayer within 30 min. Compared to the TBHP group, the NACA+TBHP group 
exhibited significantly greater electrical resistance (Figure 4A). Dextran permeability in 




Figure 4. Protective effects of NACA on paracellular permeability in HRPEpiC. 
(A) Results of TEER measurement. (B) Results of dextran permeability assays. 
 
 
3.5. CELL VIABILITY AND LETHAL EFFECTS OF TBHP ON HRPEPIC  
To investigate cell survival in response to ROS generation, cell viability assays 
were performed after treatment (Figure 5). Pretreatment with NACA alone did not affect 
cell viability (91.1 ± 4.5%), as compared to control (100.0 ± 10.1%). Cell viability was 
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reduced in the TBHP group (52.2 ± 5.5%, P < 0.001). Pretreatment with NACA provided 




Figure 5. Effects of NACA and TBHP on HRPEpiC cell viability. 
 
 
3.6. ANNEXIN V-FITC AND 7-AMINOACTINOMYCIN-D (7-AAD) DETECTION 
OF APOPTOSIS BY FLOW CYTOMETRY  
NACA has multiple antioxidant properties. It is a well-known GSH prodrug and a 
free radical scavenger 
[18-20]
. In cell-free systems, NACA can non-enzymatically restore 
GSH through thiol-disulfide exchange with the oxidized form, GSSG [21]. An annexin 
V-FITC and 7-AAD double staining assay was performed. Cells in the early apoptotic 
stages only bound annexin V-FITC, while cells in late apoptotic stages bound both 
annexin-V-FITC and 7-AAD. Dead/necrotic cells may only exhibit 7-AAD fluorescence, 
due to membrane disintegration and subsequent loss of phosphatidylserine. Table 1 
summarizes the percent distribution of viable cells and cells in the early and late stages of 
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apoptosis. The percentages of viable cells in the TBHP and NACA+TBHP groups were 
very similar (64.0 ± 4.9 % versus 67.8 ± 9.9 %). There was no significant difference in 
the number of dying cells (defined as the total of early- and late-stage apoptotic cells) 
between the TBHP and the NACA+TBHP groups (20.5 ± 6.1% versus 20.8 ± 4.8%). 
Because no significant improvement was observed in the cells pretreated with NACA, the 
dosing protocol was modified slightly without changing the total NACA exposure time 
(see Methods). Results of the modified treatment protocol are shown in Figure 6 and 
Table 2.  In the NACA+TBHP (co-exposed) group, the percentage of viable cells (88.6 ± 
0.1%) was significantly higher than that in the TBHP group (48.5 ± 5.1%, P < 0.001). 
The percentages of dying cells in the TBHP group and the NACA+TBHP co-exposure 
group were 16.5 ± 3.6% and 5.5 ± 0.8%, respectively. 
 
 
Table 1. Percent distribution of viable cells and cells in the early and late stages of 
apoptosis after 4 hours of pretreatment with NACA followed by 3 hours of TBHP 
exposure. 
Groups Control 2 mM NACA 0.5 mM TBHP NACA+TBHP 
Viable cells 94.8 ± 1.3 93.7 ± 0.5 64.0 ± 4.9 67.8 ± 9.9 
Early apoptotic cells 1.3 ± 0.6 3.0 ± 1.1 1.8 ± 0.8 2.1 ± 0.4 
Late apoptotic cells 1.9 ± 0.2 2.1 ± 0.5 18.8 ± 5.4 18.6 ± 4.9 






Figure 6. Flow cytometry analysis of apoptotic cells following the modified (co-
exposure) protocol with NACA and TBHP. 
The dot plots show a two-parameter analysis of fluorescence intensity of annexin-V FITC 
(FL1) and 7-AAD (FL3). 
 
 
Table 2. Percent distribution of viable cells and cells in the early and late stages of 
apoptosis from Figure 6. 
Groups Control 2 mM NACA 0.5 mM  TBHP  NACA+TBHP  
Viable cells 90.4 ± 1.2 84.8 ± 4.2 48.5 ± 5.1
a
 88.6 ± 0.0
b
 
Early apoptotic cells 2.2 ± 0.3 1.7 ± 0.9 2.2 ± 1.0 2.3 ± 0.3 
Late apoptotic cells 2.5 ± 0.4 4.4 ± 0.2 14.3 ± 3.5 3.1 ± 0.5 
The results are shown as mean % of total cells ± SD. (a, P < 0.001 compared to control 




4. DISCUSSION  
In this study, we evaluated the potential of NACA to prevent oxidative stress-
related damage in vitro in HRPEpiC. This allowed for evaluation of NACA as a defense 
against TBHP-induced oxidative injury. Selection of the best in vitro analogue to RPE in 
AMD patients was vital to the clinical relevance of our results. Currently, there are three 
cell models being used to study the effects of oxidative stress on the RPE: ARPE-19, fetal 
human RPE cells (fhRPE) and primary culture adult human RPE 
(e.g., HRPEpiC). ARPE-19 is a spontaneously arising retinal pigment epithelia cell line 
derived from normal eyes. The fhRPE and HRPEpiC are primary cultures of fetal 
and adult human RPE cells, respectively. When compared to ARPE-19, the fhRPE cells 
were healthier; however, adult human RPE were more physiologically representative 
of the mature function of RPE than fhRPE 
[21, 22]
. Thus, an adult human primary RPE 
cell model was used for the experiments detailed here. 
The RPE of the macula is particularly vulnerable to oxidative damage due to 
increased O2 exposure, photo-oxidation, elevated metabolic activity, and high proportion 
of polyunsaturated fatty acids 
[5]
. Our data demonstrates that TBHP increased ROS levels 
in a dose-dependent manner, leading to severe oxidative stress in the HRPEpiC cultures, 
and that NACA pre-incubation prevented TBHP-induced ROS production in HRPEpiC. 
It has been shown that accumulation of ROS induces severe oxidative stress in RPE cells, 
which is manifested by a significant reduction in levels of GSH (the most critical 
antioxidant and redox buffer of the cell) 
[23, 24]
. Results from our study showed a 
significant decrease in GSH levels in the HRPEpiC, when compared to those of the 
control group (Figure 2). Pretreatment with NACA significantly increased GSH levels, 
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which may indicate that NACA replenished GSH levels, leading to a reversal of oxidative 
stress. The protective effects of NACA are probably mediated by a number of pathways, 
which may include supplying cysteine for GSH biosynthesis, reducing extracellular 
cystine to cysteine, and converting GSSG to GSH by the action of GR and by non-
enzymatic thiol disulfide exchange 
[12, 25-27]
. Our results are in agreement with previous 
studies which reported an increase in GSH levels after NACA incubation and a decrease 
in GSH levels upon TBHP treatment in an ARPE cell line 
[11, 14]
. 
Importantly, changes in GR activity were also observed. GR regenerates GSH 
from GSSG and plays an important role in GSH homeostasis 
[28]
. NACA treatment 
increased the levels of GSH and restored GR activity (Figure 3). Our results are in line 




In the retina, the RPE forms the blood-retinal barrier (BRB) with tight junctions 
that control the exchange of nutrients and metabolites between the retina and the 
underlying choriocapillaris. It is thought that oxidative stress may induce changes in the 
BRB, which may contribute to the pathogenesis of retinal degeneration. To investigate 
and determine the ability of NACA to preserve the BRB function, membrane integrity 
after TBHP exposure was evaluated using dextran permeability and TEER assays 
[30]
. 
NACA prevented TBHP-induced reduction in TEER, verifying its ability to protect 
cellular homeostasis and outer BRB integrity under severe oxidative stress conditions. A 
similar decrease in TEER has been reported in another study, where human embryonic 
stem cell (hESC)-derived RPE cells and ARPE-19 cells were exposed to hydrogen 
peroxide 
[30, 31]
. These results are also in agreement with a previous study performed in 
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our laboratory using the ARPE-19 
[14]
. However, we did not observe any significant 
difference in dextran permeability upon NACA treatment, which could be due to a lower 
sensitivity of dextran permeability when compared with TEER 
[32]
. 
The decline in GSH observed created a redox imbalance that enhanced cell 
susceptibility to injury and ROS-induced apoptosis. Altering the redox state to a more 
reduced environment by addition of GSH has been shown to decrease sensitivity of RPE 
cells to apoptosis from ROS 
[33, 34]
. We initially investigated the protective effect of 
NACA pretreatment by studying cell viability. However, no significant improvement was 
noted by either the Calcein-AM or flow cytometry assay in cell survival. Therefore, we 
modified our study design to co-exposure along with pre-incubation and dramatically 
improved cell survival (Figure 6). It is possible that pretreatment alone is not sufficient to 
address multiple oxidative stress-related apoptotic mechanisms. Oxidants, such as 
TBHP, may induce apoptosis through two different pathways:  (1) Fas-Fas 
ligand activation and (2) mitochondrial damage and subsequent release of cytochrome c 
[35]
.  Because the interplay between these two pathways is complex, it is plausible 
that antioxidant treatments, while producing a more favorable redox status in a 
cell, may not fully address both apoptotic pathways.  In addition, the concentrations of 
TBHP (0.5 mM) and NACA (2 mM), used in our investigation, may have been too high 
and low, respectively, so that pretreatment with NACA did not provide any significant 
cytoprotection. Our previous studies with ARPE-19 indicated that up to 10 mM of NACA 







This study demonstrated that treatment of retinal pigment epithelium with NACA 
protects against oxidative stress-induced cellular injury. NACA also inhibited oxidative 
stress-related breakdown of the blood-retinal barrier as measured by TEER. The proposed 
mechanism of action involves NACA scavenging existing reactive oxygen species and 
increasing levels of reduced glutathione. With the prevalence of AMD and other retinal 
degeneration disorders that are expected to double in the coming decades, the 
development of more effective therapies to prevent their progression is imperative. Our 
results indicate that NACA has the potential to become an effective therapeutic agent by 
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1. TBHP increased intracellular ROS levels in HRPEpiC, and NACA prevented ROS 
generation.  
2. Dose-dependent GSH depletion by TBHP was prevented by pretreatment with 
NACA. 
3. Pretreatment with NACA preserved of GR activity.  
4. NACA inhibited oxidative stress-related breakdown of HRPEpiC monolayer 
paracellular permeability. 
5. NACA significantly improved cell survival when administered prior to and during 
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Oxidative stress is considered to be a major factor in the development of age-
related macular degeneration (AMD), and the neuroretina is more sensitive to oxidative 
insult when compared to the retinal pigment epithelium (RPE). We hypothesized that N-
acetylcysteine amide (NACA) would protect the neuroretina and retard progression of 
retinal degeneration. Sodium iodate (NaIO3)-treated C57BL/6 mice were used to evaluate 
the therapeutic potential of NACA eye drops by assessing visual and photoreceptor 
function through electroretinogram (ERG) and measurements of the outer nuclear layer 
(ONL) thickness, the phosphatase and tensin homolog deleted on chromosome ten 
(PTEN), and oxidative stress parameters (such as glutathione (GSH), cysteine, and 4-
hydroxynenal (4-HNE) levels). Our results indicated that NACA eye drops partially 
prevented the reduction in the ERG waveform peak amplitudes measured 36 hours after 
NaIO3 injection. Furthermore, NACA eye drops prevented reduction in ONL thickness.  
Significant increases in GSH, cysteine, 4-HNE, and PTEN were observed, but were 
reversed upon treatment with NACA eye drops in this animal model. These results 
illustrated that NACA eye drops partially prevent photoreceptor degeneration and loss of 
visual potential 36 hours after NaIO3 injection. Accordingly investigations of this potent 





Age-related macular degeneration (AMD) is the leading cause of irreversible 
blindness in the industrialized world and the third leading cause worldwide 
[1]
. This 
creates an annual direct health care cost of $4.6 billion in the U.S. 
[2]
. Unfortunately, 
patients with AMD lose quality of life, as they need assistance in their daily tasks of 
simply walking, reading, or driving 
[3]
. 
AMD is a complex disease affected by senescence, genetic predisposition, 
environmental factor, and oxidative stress, all of which may contribute to its pathogenesis 
[4, 5]
. AMD preferentially affects the macula—the central region of the retina. Due to its 
high oxygen tension, high metabolic rate, and a greater proportion of polyunsaturated 
fatty acids (PUFAs), the macula is subject to increased levels of photo-oxidative stress 
[6-
9]
. The endogenous antioxidants, such as GSH, in the retinal tissue support the redox 
balance that is crucial to maintaining healthy retinal pigment epithelial (RPE) cells and 
normal function of the eye 
[10]
. Exogenous oxidative stress is potentiated by the relative 
paucity of antioxidants in an aging retina. Light-induced peroxidation of shed 
photoreceptor outer segments containing PUFAs leads to the formation of toxic reactive 
oxygen species (ROS) and lipofuscin 
[11-13]
. AMD is classified as dry (non-exudative) or 
wet (exudative) clinically. Non-exudative disease is characterized by RPE death, or 
geographic atrophy. Attenuation of the overlying photoreceptors, which are located in the 
outer nuclear layer, follows retinal pigment epithelial demise. The distinguishing feature 
of wet AMD is choroidal neovascularization, followed by exudation and hemorrhaging as 
the disease worsens. If left untreated, dry AMD may progress to wet 
[14, 15]
; however, this 
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can be halted if a therapeutic intervention is initiated early enough during the course of 
the disease. 
Research efforts, using antioxidants to treat AMD, are plentiful because oxidative 
stress is one of the most important causes of AMD 
[16, 17]
. Currently, the only available 
treatment to slow the progression of visual loss in dry AMD includes vitamin and 
micronutrient supplementation, cessation of smoking, and dietary modification 
[18, 19]
.  In 
large prospective trials, like the Age-Related Eye Disease Study (AREDS), a wide variety 
of nutrients, such as vitamins, ω-3 fatty acids, antioxidants (β-carotene and vitamins C 
and E), zinc, lutein, and zeaxanthin were studied 
[5, 20]
. The results of these studies were 
inconclusive; therefore, there is a dire need to develop an effective treatment for AMD. 
An ideal therapeutic agent should be highly bioavailable, non-toxic, easy to use, 
economical, and should limit oxidation, boost anti-oxidative mechanisms, and even 
reverse existing damage. One such candidate is N-acetylcysteine amide (NACA), a thiol 
antioxidant that has demonstrated beneficial effects on oxidative-stress related eye 
disorders 
[21-25]
. Because AMD has a multifactorial etiology, no single animal model can 
fully recapitulate all of its pathologic features. Sodium iodate (NaIO3), a stable oxidizing 
agent, was first used in a model of retinal degeneration by Sorsby in 1941 
[26]
. Since then, 
the systemic exposure of NaIO3 has been an effective way to induce retinal degeneration 
and retinal pigment epithelium atrophy. Thus this model was a very appropriate model to 
use for evaluating therapeutic approaches to retinal degeneration 
[27]
. NaIO3 induces both 
retinal pigment epithelium degeneration and altered neurosensory function via separate 
cell-death pathways: necrosis in RPE and caspase-dependent apoptosis in photoreceptors 
[28-30]
. Surprisingly, the photoreceptors seemed more vulnerable to oxidative insult, as 
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compared to RPE 
[29]
. Other studies have suggested that necroptosis is a major 
mechanism for RPE cell death in response to oxidative stress in the AMD and apoptosis 
is the major mechanism for photoreceptor cell death in response to oxidative stress 
[31, 32]
. 
Because the pathogenic mechanism of the AMD still remains unclear, antioxidants have 
garnered much interest in laboratory and clinical studies 
[18, 33, 34]
. 
The tumor suppressor PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) has three primary functions: cell adhesion and lipid phosphatase as well 
as protein phosphatase activities. PTEN plays a critical role in the organization of RPE 
cell junctions and adhesion 
[35]
. The phosphatase activity of PTEN can recover junctional 
β-catenin and can suppress the epithelial-to-mesenchymal transition, thereby inhibiting 
the cell migration associated with the onset of retinal degeneration. The catalytic activity 
of PTEN is modulated by ROS. The presence of oxidants in the cellular environment can 
lead to inactivation of PTEN by phosphorylation, which disturbs the RPE adhesion 
structure and initiates RPE degeneration. In an advanced tumor cell, free fatty acid-
induced oxidative stress is mediated by phosphorylates PTEN and suppression of PTEN 
monoubiquitination, which results in nuclear export of PTEN 
[36]
. PTEN inactivation and 
the resulting Akt activation are inhibited by antioxidant treatment 
[37]
. PTEN also 
regulates retinal interneuron morphogenesis and synaptic layer formation 
[38]
. In 
summary, PTEN is strongly linked with ROS and PI3K/Akt cell survival signaling 
pathways. 
 Ercal’s group has extensively investigated the use of thiol antioxidants, 
particularly NACA, in oxidative stress-related eye disorders including cataracts and light-
induced retinal degeneration 
[21-23, 25, 39]
. Their results showed that NACA restored GSH 
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levels and activities of glutathione reductase (GR), glutathione peroxidase (GPx) and 
catalase in L-buthionine-(S, R)-sulfoximine (BSO)-induced cataracts in rats 
[21]
. NACA 
maintained outer nuclear layer thickness and RPE cell integrity in mice exposed 
phototoxic light 
[23]
. In previous eye-related investigations, NACA was given as an 
injection; however, an eye drop formulation would be more desirable and more 
conveniently administered in both a clinical setting and by patients themselves. 
Accordingly, this study was designed to formulate a type of NACA eye drops that can be 
more conveniently administered in real-life cases, to protect the neuroretina against 
oxidative stress-induced damage. An understanding of the protective role of NACA 




2. MATERIALS AND METHODS 
2.1. MATERIALS 
N-acetylcysteine amide (NACA) was provided by Dr. Glenn Goldstein (David 
Pharmaceuticals, New York, NY, USA). C57BL/6 mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). Other chemicals were ordered from Sigma (St. 
Louis, MO, USA), unless otherwise indicated. 
2.2. ANIMAL MODEL AND EXPERIMENTAL DESIGN 
Seven-week-old male C57BL/6 mice were received and housed in a temperature- 
and humidity-controlled (about 22°C and 55%) animal facility, with a 12-hour light and 
dark cycle. The animals had free access to rodent chow and water, and animals were 
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acclimatized for 1 week before experiments were performed. All animal procedures 
conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research and were approved by the Institutional Animal Care and Use Committee of 
Missouri University of Science and Technology. 
Eight-week-old C57BL/6 mice received 0.1% NACA eye drops (in 25 mM 
phosphate buffer, pH = 7.4) or phosphate buffer bilaterally twice a day, every other day 
for 4 weeks. After dosing with NACA for 4 weeks, the mice received one intraperitoneal 
(IP) injection of 75 mg/kg NaIO3, and then eye drops were continued for another week. 
On the final day of the experiment, mice were anesthetized by an IP injection of 
ketamine (120 mg/kg) and xylazine (16 mg/kg), and cervical dislocation was used for the 
secondary euthanasia method. Retinas were removed under a dissecting microscope and 
immediately placed in liquid nitrogen for further analysis. 
2.3. ELECTRORETINOGRAPHY (ERG) 
After adaptation for 10-12 hours in the dark, ERGs were recorded in mice under 
anesthesia induced by isoflurane 
[40]
 (Butler Schein, Dublin OH) (2.25% for induction 
and 1.25% maintenance). Mice were placed on a heating pad to maintain their body 
temperature during anesthesia. Proparacaine hydrochloride ophthalmic solution and 
tropicamide (0.5%, Akorn Inc, IL, USA) were used as the topical anesthetic and 
mydriatic, respectively. The recording electrode was placed in a drop of methylcellulose 
on the surface of the cornea, a reference electrode was placed subdermally at the vertex 
of the skull, and a ground electrode was placed subdermally at the base of the tail. 
Scotopic and photopic ERGs were recorded and processed using a HMsERG LAB 
system and ERGView 2.5 analytical software 
[41]
 (OcuScience, Henderson, NV, USA). 
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ERG procedures started with a scotopic intensity series from -3 to 1 log (cd∙s/m2). 
Photopic ERGs were recorded after light adaption (10000 mcd∙s/m2) for 5 min (mcd: 
millicandelas). 
2.4. HEMATOXYLIN AND EOSIN (H&E) STAINING 
Eyes were enucleated and fixed in 4% paraformaldehyde overnight. Briefly, the 
eyes were then embedded in paraffin, and serial 5 µm sagittal sections of the whole eye 
were cut through the cornea to the optic nerve. Paraffin-embedded serial sections of 
retina were deparaffinized with xylene and absolute ethanol, rehydrated with distilled 
water, stained with hematoxylin solution, and counterstained with eosin. 
2.5. OUTER NUCLEAR LAYER (ONL) THICKNESS MEASUREMENT 
In each fixed and H&E-stained eye (n = 3 mice), ONL thickness was measured at 
40-μm intervals across 400-µm sections of the parafoveal area, located 500 µm from the 
optic nerve head. Images were analyzed at 20X objective magnification using ImageJ 
image processing software (Version 1.49, NIH). For every group, ONL thickness at each 
interval was averaged, and statistical analysis was performed. 
2.6. 4-HYDROXYNONENAL (4-HNE) IMMUNOHISTOCHEMISTRY STAINING 
AND QUANTIFICATION 
Briefly, serial sections adjacent to those designated for H&E staining were taken 
from paraffin-embedded eyes (n = 3 mice). Sections were deparaffinized, rehydrated, 
blocked, and incubated overnight at 4°C with anti-4HNE antibody (1:100 dilution; 
ab46545, Abcam, MA, USA) using 3,3'-Diaminobenzidine (DAB) as the chromogen 
(which indicates the presence of 4-HNE as a dark brown stain) and hematoxylin as the 
counterstain. Images were examined at 100X objective magnification for quantification 
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of 4-HNE levels, using ImageJ to determine the proportion of dark brown area to the total 
image area in the ONL. 
2.7. MEASUREMENT OF INTRACELLULAR GLUTATHIONE (GSH) AND 
CYSTEINE LEVELS 
Mice (n = 5) were sacrificed and eyes were enucleated and dissected under a 
dissection microscope to verify isolation of the retina without RPE contamination. The 
retinas were homogenized in 250 µL of cold serine borate buffer (pH 7.5). GSH and 
cysteine were separated and quantified by HPLC with fluorescence detection (Finnigan 
Surveyor FL Plus, Thermo Scientific, USA) after derivatization with N-(1-
pyrenyl)maleimide (NPM) 
[42-44]
. Protein levels of the homogenates were measured by the 
Bradford method 
[45]
 (BioRad Laboratories, Inc., CA, USA). 
2.8. SDS-PAGE AND WESTERN BLOT FOR PTEN AND PHOSPHO-PTEN (P-
PTEN) ANALYSIS 
Protein levels of the cell homogenates were measured by bicinchoninic acid 
(BCA) protein assay. 25 μg protein samples (n=3 mice) were separated in NuPage 12% 
Bis-Tris gels (Life Technologies, Grand Island, NY). Anti-PTEN (Cat # 9552) and anti-
p-PTEN (Ser380/Thr382/383; 1000 dilutions; Cat # 95541, Cell Signaling, MA, USA) 
were used as the first antibody, and GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) (1:1000 dilutions; Cell Signaling) was used as the dominant 
housekeeping gene. SuperSignal Chemiluminescent Substrate was used to visualize 
PTEN bands. Membrane was stripped after PTEN measurement, and the procedure was 
repeated for anti-p-PTEN. SuperSignal West Pico Chemiluminescent Substrate and 




2.9. STATISTICAL ANALYSIS 
All reported values were represented as the mean ± SD (n ≥ 3). Statistical analysis 
was performed using GraphPad Prism 5.01 software (GraphPad Software Inc., La Jolla, 
CA). Statistical significance was ascertained by one-way analysis of variance (ANOVA) 
and Tukey’s multiple comparison tests. Statistical significance was set at P < 0.05 (*, P < 




3.1. PARTIAL PREVENTION OF SODIUM IODATE-INDUCED VISUAL LOSS 
BY NACA 
In order to investigate the effect of NACA on NaIO3-induced retinal dysfunction, 
electroretinography was performed 36 hours and 6 days after a NaIO3 injection. Figure 1 
is a subset of data in scotopic view at 3000 mcd∙s/m2 showing the mixed rod and cone 
response. Figure 1A is the average of the subset ERG data obtained 36 hours after NaIO3 
IP injection. Figure 1B-1F shows the data from day 6. The first negative peak was the a-
wave, which was followed by the large, positive b-wave. The a-wave and b-wave 
represent the health of outer and inner retina, respectively. The a- and b-wave amplitude 
were attenuated and the implicit time prolonged in the aged eye. The average a-wave 
amplitudes in the control and NACA groups were 220.0 μV and 187.5 μV, respectively. 
Application of NaIO3 led to a significant reduction in all ERG waveform peak amplitudes 
and increased a-wave implicit time. The average a-wave amplitude in the NaIO3 group 
was 12.4 μV. In contrast, the mean a-wave amplitude measured in the NACA+NaIO3 
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group was 181.7 μV. However, the a-wave implicit times were increased in both NaIO3 
and NACA+NaIO3 groups. On day 6, the a-wave amplitude in the control, NACA, NaIO3 
and NACA+NaIO3 group were 203.5 ± 28.7, 261.3 ± 26.3, 43.9 ± 17.6 and 27.4 ± 11.0 
μV, respectively. The b-wave amplitude in the control, NACA, NaIO3 and NACA+NaIO3 
group were 377.0 ± 54.7, 501.7 ± 80.7, 47.2 ± 21.8 and 19.0 ± 4.7 μV, respectively. The 
average of a- and b-wave amplitude and implicit time are shown in Figure 1C-1F. 
3.2. NACA PREVENTS OXIDATIVE DAMAGE AND OUTER NUCLEAR 
LAYER (ONL) THINNING 
To investigate the ability of NACA eye drops to prevent photoreceptor death, the 
thickness of the ONL, which contains rod and cone cell bodies, was measured. 
Representative images of H&E-stained retinal sections are shown in Figure 2A, and the 
averaged ONL thickness is shown in Figure 2B. In the NaIO3 group, significant loss of 
RPE and associated photoreceptor disorganization were observed. The outer segment 
layer of rods and cones was markedly reduced, and the boundary between the inner and 
outer segments (IS and OS) was lost. ONL folding and thinning were also detected. The 
averages of the ONL thickness in the control and NACA groups were 54.48 ± 3.32 and 
55.7 ± 4.97 μm, respectively. The ONL thickness was significantly reduced in the NaIO3 
group (32.96 ± 4.12 μm) as compared to the control group, but NACA eye drops 
significantly prevented ONL thinning (43.87 ± 7.89 μm) (***, P < 0.001). 
3.3. EFFECTS OF NAIO3-INJECTION AND NACA EYE DROPS ON RETINAL 
GSH AND CYSTEINE LEVELS 
To determine the effects of oxidative stress, retinal tissues (n = 5) were dissected 
and collected on day 7 after injection of NaIO3 in order to measure GSH and cysteine 
levels. GSH levels (Figure 3A) in the sodium iodate group were slightly increased (26.0 ± 
1.1 nmol/mg protein) compared to the control group (23.5 ± 0.9 nmol/mg protein) (P < 
96 
 
0.001).  The GSH levels in the NACA group were 22.4 ± 1.1 nmol/mg protein, which 
was close to the control group. The cysteine levels (Figure 3B) in the control, NACA, 
NaIO3 and the NACA+NaIO3 groups were 0.6 ± 0.1, 0.5 ± 0.1, 5.6 ± 1.1 and 4.0 ± 1.2 
nmol/mg protein, respectively. The cysteine levels in the NaIO3 group were significantly 
higher than in both the control and NACA groups (P < 0.001). 
 
 
Figure 1. Partial prevention of sodium iodate-induced retinal dysfunction. 
A represents ERG subset data in scotopic view at 3000 mcd∙s/m2 showing mixed rod and 
cone response (n = 4-6). A) ERG data were obtained 36 hours after NaIO3 IP injection. 
The a-wave and b-wave amplitudes were decreased and the implicit time was prolonged 
in the NaIO3-only group. Pretreatment with NACA eye drop partially prevented 
reductions in all ERG waveform peak amplitudes when compared to the NaIO3-treated 
group. B) ERG data were collected on day 6 after NaIO3 injection (one day before 
sacrifice). A-wave and b-wave are attenuated in the NaIO3 group. (C-F) Data analysis of 
(B): (C) a-wave amplitude. (D) a-wave implicit time. (E) b-wave amplitude. (F) b-wave 







Figure 2. NACA prevents oxidative damage and outer nuclear layer thinning. 
(A) A representative image of H&E staining for retinal sections showing prevention of 
ONL thinning by NACA eye drop (A double-headed arrow indicates the ONL).  




Figure 3. Thiol levels in retina. 





3.4. REDUCTION OF LIPID PEROXIDATION BY-PRODUCT 4-HNE BY NACA 
IN ONL 
To evaluate the ability of NACA to prevent lipid peroxidation, retinal samples 
were stained for 4-HNE adducts by immunohistochemistry. A representative image of the 
4-HNE stain is shown in Figure 4A. A greater proportion of brown color in a given area 
indicated more 4-HNE adduct formation as demonstrated in Figure 4B. The averages (n = 
4) of 4-HNE adduct-stained areas relative to the total stained area in each group were as 
follows: 0.49 ± 0.03 in the control group, 0.47 ± 0.05 in the NACA group, 0.67 ± 0.03 in 
the NaIO3 group, and 0.5 6± 0.05 in the NACA+NaIO3 group. The 4-HNE levels were 
significantly increased in the NaIO3 group (P < 0.01, compared to control) and decreased 







Figure 4. Reduction of lipid peroxidation by-product formation in ONL 
(A) Immunohistochemical detection of 4-HNE adducts in retina (40X objective).  
(B) Quantification of 4-HNE levels in ONL (A double-headed arrow indicates the ONL) 





3.5. PTEN AND PHOSPHORYLATED-PTEN (P-PTEN) IN THE RETINA 
In order to evaluate the PTEN and phosphorylated PTEN (p-PTEN) levels in the 
retina of mice treated with NaIO3, PTEN and p-PTEN were analyzed using the Western 
blot. Figure 5A and 5B show the Western blot and the quantitated results for PTEN and 
p-PTEN, respectively. The calculated PTEN/p-PTEN ratio is shown in Figure 5C. 
PTEN levels in the NaIO3 group were 1.22 times greater than the control, and the 
NACA+NaIO3 group PTEN levels were 1.07 times greater than the control. The p-PTEN 
levels were increased in the NaIO3-injected group but not significantly when compared 
with the control group; however, p-PTEN levels were significantly lower in the 
NACA+NaIO3 group (P < 0.05). The average of PTEN/p-PTEN ratio in control, NACA, 
NaIO3 and NACA+NaIO3 group were 1.003, 0.98, 1.12 and 1.23, respectively. The 
PTEN/p-PTEN ratio in the NACA+NaIO3 group was significantly higher (P < 0.05). 
 
 
Figure 5.  PTEN and phosphorylated-PTEN (p-PTEN) in the retina. 
Western blots and quantitated results for PTEN (A), p-PTEN (B). (**, P < 0.01 and *, P 








NaIO3-induced retinal degeneration in a C57BL/6 mouse model was used to 
investigate the effects of NACA eye drops as treatment for oxidative stress-induced 
retinal degeneration. NaIO3 is a stable oxidizing agent that has been employed in many 
retinal degeneration studies, and systemic administration has been reported to selectively 
impair the RPE, which leads to loss of photoreceptors 
[46]
. However, NaIO3 can also 
directly impair the neuroretina in vitro and in vivo models 
[29, 47]
, and the neuroretina 
seems to be more vulnerable to NaIO3-induced damage compared to the RPE in vivo 
[29]
. 
The underlying molecular mechanisms of NaIO3 toxicity include activation of Akt, 
reduction in RPE-specific protein (RPE65), accumulation of ROS in mitochondria, 
impairment of Nrf2 signalling, and inactivation of PTEN in cell adhesion 
[27, 29, 35]
.  In a 
C57BL/6 model, systemic exposure to NaIO3 at low concentrations can induce rapid 
dysregulation of phototransduction genes in the neuroretina, including  Rho, OPn1mw, 
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and Pde6b,  as well as reduction in a- and b-wave amplitudes by day 3 and total loss by 
day 8 at higher concentrations 
[29]
. 
N-acetylcysteine (NAC), a thiol antioxidant, has been used clinically to treat 
various disorders and is already approved by the FDA (the U.S. Food and Drug 
Administration). However, NACA, the amide derivative of NAC, has been shown to be 
more effective because of its neutral charge, which increases its ability to permeate cell 
membranes and the blood-neural barrier 
[48]
. Independent research with NACA has 
demonstrated its improved penetration of cell membranes as compared to other 
antioxidants including NAC, vitamin E and carotenoids 
[49, 50]
. This potent antioxidant 
functions by directly scavenging free radicals and indirectly by providing cysteine for 
GSH synthesis, substituting itself for depleted GSH, and chelating Cu
2+ 
that can catalyze 
ROS formation 
[51]
. From the literature, NACA possesses antioxidant, anti-apoptotic, and 
anti-inflammatory properties 
[48]
. As an antioxidant, NACA can scavenge radicals, 
chelate Pb(II), and participate in thiol-disulfide exchange between GSSG and NACA to 
replenish GSH in vitro 
[39, 49, 52, 53]
. 
In our study, visual function was assessed using the flash electroretinography 
(ERG), a non-invasive method 
[54]
. Using this model, we demonstrated that NACA 
partially maintained visual function for a short time after administration of a high dose of 
NaIO3 (75 mg/kg), but it was unable to halt progression of retinal degeneration for the 
duration of the experimental time period.  The subset of ERG in the scotopic view at 
3000 mcd∙s/m2 represented a combined rod and cone response. The first negative a-wave, 
also called the “late receptor potential,” was generated by photoreceptor 
hyperpolarization and reflected the general physiological health of the photoreceptors in 
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the outer retina 
[55]
. In contrast, the following positive b-wave reflected the health of the 
inner layers of the retina, including the ON bipolar cells and the Muller cells 
[46, 56, 57]
. 
Our data demonstrated that NaIO3 significantly impaired photoreceptor hyperpolarization 
and post-phototransduction (Figure 1A-1B) and that NACA eye drops partially prevented 
this loss of visual function 36 hr after NaIO3 injection. By the end of the study, however, 
NACA eye drops failed to prevent visual function loss. ROS can activate STAT3 (a 
transcription factor), which induces rhodopsin degradation via the ubiquitin-proteasome 
system. The resulting visual function impairment manifests as subnormal a-wave and b-
wave measurements, which other research has shown 
[58-61]
. NaIO3 can damage the 
synapse between photoreceptors and depolarized bipolar cells, which results in a 
diminished ERG b-wave 
[29, 62]
. 
ONL thickness was used as a metric for photoreceptor cell health. NaIO3-induced 
damage to the outer segment (OS) and inner segment (IS) may explain the diminished a-
wave and b-wave in our ERG results. NACA eye drops prevented the NaIO3-induced 
thinning of the ONL, verifying its ability to partially preserve visual function as 
determined by ERG; however, the NaIO3-induced RPE damage did not improve with 
NACA eye drops (Figure 2A). 
GSH is the most abundant and critical antioxidant and redox buffer of the cell, 
and fluctuations in GSH levels following oxidative insult are largely dependent on the 
anti-oxidative capacity of the cell and time course of its response 
[63-65]
. In this study GSH 
was found to be increased in the NaIO3 group, which may have been the result of 
initiation of cellular defense against oxidative stress. There are many examples of GSH 
up-regulation under oxidative stress 
[25, 66, 67]
. In addition to the altered GSH level, a 
103 
 
significant increase in the cysteine level was observed in the NaIO3 group. This may have 
contributed to the rise in GSH levels, as cysteine availability is the rate limiting factor for 
GSH synthesis. The age of the of animals used in our study may also have affected GSH 
levels, due to their increased Nrf2 expression, as compared to older animals (noted by 
Sachdeva et al. 
[68]





Although the cysteine level was significantly 
lower in the NACA+NaIO3 group, it was still higher than in the control group. 
Our results also showed that NACA decreased NaIO3-induced lipid peroxidation 
in the ONL, which was measured by 4-hydroxynonenal (4-HNE) formation. Free radical 
chain reactions, initiated by oxygen or light, can damage molecules in the photoreceptor 
outer segments containing large concentrations of long-chain PUFAs that are particularly 
susceptible to lipid peroxidation and form toxic by-products such as malondialdehyde 
(MDA) and 4-HNE, which have been measured in the ONL in other studies 
[71]
. Lipid 
peroxidation by-products can induce further production of ROS 
[72]
, which overwhelms 
repair mechanisms and ultimately leads to photoreceptor death and impaired visual 
potential. This is consistent with our ERG results and ONL thickness measurements. 
To gain further insight into the mechanism of retinal degeneration induced by 
NaIO3, we quantified the levels of phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) and phosphorylated PTEN (p-PTEN), using Western blot. PTEN 
can be inactivated by either phosphorylation or thiol oxidation 
[73, 74]
, and it has been 
shown that phosphorylation of PTEN at specific residues, namely Ser380, Thr382, or 
Thr383, decreases its association with junctional proteins 
[35]
. Our results showed both 
PTEN and p-PTEN levels were increased in the NaIO3 group. PTEN lipid phosphatase 
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However, when PTEN was inactivated, the resulting 
upregulation of mTORC1 through increased PI3K/Akt signaling can prolonged cone 
photoreceptor survival even during RPE cell malfunction or death in the NaIO3 model 
[77]
. Similar to its effect on GSH levels, NaIO3-induced PTEN elevation may be the result 
of an active cellular defense against oxidative stress. Inactivation of PTEN leads to an 
epithelial-to-mesenchymal transition of RPE cells resulting in their migration out of the 
retina. Other independent studies, however, indicate that PTEN can be phosphorylated by 
ROS-activated PI3K 
[78]
. Although ROS inactivation of PTEN is usually transient, 
compromised antioxidant defenses in aged RPE cells might fail to protect PTEN, leading 
to longer-term inactivation 
[77]
. 
In summary, NACA eye drops exhibit some protective effects against NaIO3-
induced neuroretinal damage in a mouse model of AMD. NaIO3-induced oxidative stress 
was evidenced by higher levels of lipid peroxidation by-product 4-HNE that was 
measured in the retina of animals receiving NaIO3 injections. Even so, elevated cysteine 
and GSH in these animals may be indicative of upregulated antioxidant defense 
mechanisms. PTEN and its inactive form, p-PTEN, play an important role in cell 
adhesion and PI3K/AKT/mTOR signaling. While both forms were found to be increased 
in the retina after NaIO3 injection, the rise in PTEN levels was proportionally greater than 
that of p-PTEN, likely downregulating survival signaling and resulting in photoreceptor 
death and ONL thinning. In NACA-treated animals, the effect on the ratio of PTEN to p-
PTEN was even more pronounced. At the cellular level, NACA eye drops prevented 
ONL thinning but did not entirely protect RPE integrity, which may explain the 
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diminished a- and b-wave waveforms observed in the ERG of these animals. Overall, 
NACA eye drops maintained partially visual function for a short time after administration 
of a high dose of NaIO3 (75 mg/kg), but NACA was unable to halt progression of 
neuroretinal damage for the duration of the experiment.  
 
 
5. CONCLUSIONS  
The primary objective of this study was to examine the effects of NACA eye 
drops on the preservation of neuroretina in a chemically-induced macular degeneration 
model. The eye drops could possibly be more conveniently administered in real-life 
cases. Our results showed that NACA eye drops provided short-term photoreceptor 
protection following NaIO3-induced damage. The increased GSH and cysteine levels in 
the NaIO3-treated groups may indicate that antioxidant defense mechanisms in the 
affected cells had been mobilized against the effects of the toxic lipid peroxidation by-
product (4-HNE) in the ONL, and NACA eye drops were able to reduce the 4-HNE 
accumulation. In real life, dry AMD is a slowly progressing disease, and once it has been 
discovered, an effective eye drop formulation may stop the progression of dry AMD to 
the more severe wet AMD. Currently, there are no available experimental animal models 
that perfectly replicate all pathological features of dry AMD. This experimental model of 
acute retinal degeneration more closely approximates advanced stages of the disease but 
is not necessarily representative of AMD pathology in the majority of patients. However, 
these results can provide valuable support for further investigation of NACA eye drops as 
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4. PRELIMINARY DATA FOR IN VITRO MODEL 
Before investigating chemically induced retinal degeneration in in vivo, we supplemented 
our research by applying the same method in vitro with HRPEpiC, a primary culture of 
human retinal pigment epithelial cells. The purpose of this study was to evaluate redox 
status following NaIO3-induced oxidative stress and the protective effects of NACA. 
4.1. RESULTS 
4.1.1. Protection by NACA Against Sodium Iodate-Induced Cell Death.  The 
cytotoxic effects of NaIO3 were evaluated in HRPEpiC after 24 hours of treatment. NaIO3 
induced cytotoxicity in a dose-dependent manner (Figure 4.1), and pre-incubation with 
0.5 mM NACA for 4 hours prior to NaIO3 treatment increased cell viability. Results are 
reported as percentage of the control. The cell viability was 65.5 ± 4.1% in the 5 mM 
NaIO3 group and 104.5 ±7.7 % in the NACA-pretreated NaIO3 group (n = 3-5). 
4.1.2. The Protective Effect of NACA Against NaIO3-Induced ROS 
Formation in HRPEpi Cells. We further investigated the protective effect of NACA 
against NaIO3-induced oxidative damage by determining levels of ROS formation in 
HRPEpiC (Figure 4.2). Fluorescence measured in the cells was indicative of intracellular 
ROS. The ROS levels in the 5 mM and 15 mM NaIO3 groups were 3.96 ± 0.13 and 4.61 
± 0.15 times that of the control group, respectively (P < 0.001). The ROS level was 3.33 
± 0.40 times that of the control in the NACA + 5 mM NaIO3 group (P < 0.05) and 3.61 ± 
0.61 times the control level in the NACA + 15 mM NaIO3 group (P < 0.001).  


































Figure 4.1 Comparison of NaIO3 cytotoxicity with and without NACA in HRPEpiC. 
Cells were pretreated with either 0.5 mM NACA or control media for 4 hours. This was 
replaced by media with various concentrations of NaIO3 in which the cells were cultured 
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Figure 4.2 ROS levels in HRPEpiC after 4 hours of pretreatment with NACA and another 





4.1.3. Intracellular Glutathione Levels. To investigate the intracellular thiol 
antioxidant levels as a consequence of NaIO3-induced ROS generation, GSH levels were 
measured at two different time points during the course of the experiment. Figure 4.3A 
shows the GSH levels after 3 hours of NaIO3 treatment, and Figure 4.3B shows the GSH 
levels after 24 hours of NaIO3 dosing. After 24 hours, the GSH levels were significantly 
increased in the 5 mM NaIO3 group (99.4 ± 9.1 nmol/mg protein, P < 0.001), but they 
were close to the control level in the 15 mM NaIO3 group. In the 20 mM NaIO3 group, 
the GSH levels were significantly decreased compared to the control group (14.1 ± 6.6 
nmol/mg protein, P < 0.001). The GSH levels in NACA + 5 mM NaIO3, NACA + 15 
mM NaIO3, and NACA + 20 mM NaIO3 groups were 88.9 ± 7.1, 26.6 ± 3.3 and 4.4 ± 3.5 
nmol/mg protein, respectively. The cysteine levels in the control, 0.5 mM NACA, 5 mM 
NaIO3, and NACA+NaIO3 groups were 0.53 ± 0.24, 1.85 ± 0.48, 1.11 ± 0.09 and 0.65 ± 
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Figure 4.3 Intracellular GSH levels in HRPEpiC. 
(A) GSH levels were measured after 3 hours of NaIO3 treatment. (B) GSH levels were 
measured after 24 hours of NaIO3 treatment with and without NACA pretreatment. 
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4.1.4. Glutathione Reductase Activity. Glutathione reductase (GR) reduces 
GSSG to generate GSH and is a very important enzyme for glutathione homeostasis. The 
GR levels in the control, 0.5 mM NACA, 5 mM NaIO3, and NACA+NaIO3 groups were 
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Figure 4.4 Glutathione reductase (GR) levels. 
NaIO3 reduced GR activity after 24-hour dosing, and pretreatment with 0.5 mM NACA 





5. PRELIMINARY DATA FOR IN VIVO MODEL 
The rd10
+/+
 strain is a spontaneous missense point mutation in Pde6 (cGMP 
phosphodiesterase 6B in rod receptors) that results in increased levels of cGMP and leads 
to elevated ROS and oxidative stress. To further assess the effectiveness of NACA eye 
drops, we utilized 1-week old rd10
+/+
 mice with C57BL/6 mice as controls. The 
experimental design is outlined in Figure 5.1. 
Because retinal degeneration begins before the rd10
+/+
 mice open their eyes on 
postnatal day (P) 17, it was necessary to change our initial research design and administer 
NACA via intraperitoneal (IP) injection to study its preventative effects. From P8, IP 
injections of either sodium phosphate buffer or 250 mg/kg NACA were administered 
once daily until P16. Eye drops (1% NACA/vehicle, 3 times daily, 4 drops per time) were 
started on P17 and continued until P25. The mice were sacrificed on P26, and the eyes 










 Our results showed that ONL thinning in rd10
+/+
 mice had been significantly 
prevented with NACA eye drops when compared to retinal sections from mice given 
buffer eye drops. Figure 5.2A shows representative images of H&E staining for retinal 







Figure 5.2 NACA eye drops prevented the reduction of ONL thickness in rd10
+/+
. 
(A)Representative images of H&E staining for retinal sections and (B) the average ONL 
























































AMD is a leading cause of irreversible blindness in the Western world. Oxidative 
stress plays a significant role in the progression of AMD, and the clinically available 
treatments are limited. With the prevalence of AMD and other retinal degenerative 
disorders expected to double in the coming decades, the development of more effective 
therapies to prevent their progression is imperative. Because these conditions are closely 
linked to oxidative stress, we designed an in vitro and an in vivo model to investigate the 
effectiveness of the thiol antioxidant NACA in preventing retinal pigment epithelial cell 
and retinal cell damage. 
In the TBHP-induced HRPEpiC model, our data indicates that TBHP generated 
ROS, which reduced cell viability, depleted GSH levels, and inhibited GR activity. The 
treatment of retinal pigment epithelium with NACA protected against TBHP-induced 
cellular injury. NACA also inhibited oxidative stress-related breakdown of the blood-
retinal barrier as measured by TEER. The proposed mechanism of action involves NACA 
scavenging existing reactive oxygen species and increasing levels of reduced glutathione. 
Our results indicate that NACA has the potential to become an effective therapeutic agent 
by enhancing antioxidant defenses while removing pathologically relevant ROS. 
In the NaIO3-induced retinal degeneration model, NaIO3 increased ROS 
generation, leading to oxidative stress and cell death. NACA pretreatment helped protect 
HRPEpiC against NaIO3-induced ROS formation, although it was not sufficient to restore 
GSH levels after depletion by NaIO3. Furthermore, we investigated the beneficial effects 
of NACA eye drops in a chemically induced retinal degeneration model. Our results 
showed that NACA eye drops improved photoreceptor function following NaIO3-induced 
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oxidative stress. NACA eye drops also reduced accumulation of the toxic lipid 
peroxidation by-product 4-HNE in the retina. These results support further investigation 
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